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Family, twin and adoption studies consistently suggest that genetic factors 
strongly influence the risk for alcohol dependence (AD).  Although the literature 
supports the role of genetics in AD, identification of specific genes contributing to 
the etiology of AD has proven difficult.  These difficulties are due in part to the 
complex set of risk factors contributing to the development of AD.  These risk 
factors include comorbidities with other clinical diagnoses and behavioral 
xi 
 
phenotypes (e.g., major depression), physiological differences that contribute to 
the differences between people in their level of response to ethanol (e.g., initial 
sensitivity) and finally the large number of biological pathways targeted by and 
involved in the processing of ethanol.  These complexities have probably 
contributed to the limited success of linkage and candidate gene association 
studies in finding genes underlying AD.  The powerful and unbiased genome-
wide association study (GWAS) offers promise in the study of complex diseases.  
However, due to the complexities of known risk factors, GWAS data has yet to 
provide consistent, replicable results.  In light of these difficulties, this dissertation 
has five specific aims which attempt to investigate genetic risk loci for AD and 
related phenotypes through improved methods for candidate gene selection, 
analysis of a pooled genome-wide association study, genome-wide analyses of 
initial sensitivity and maximum alcohol consumption in a twenty-four hour period 
and finally, creation of a multivariate AD/internalizing phenotype. 
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CHAPTER ONE 
 
 
 
Global Introduction 
Alcohol dependence (AD) is a debilitating and chronic disorder with lifetime prevalence 
estimates in the United States of 20% in males and 10% in females (Kessler, Crum et 
al. 1997, Grant 1997).   Harmful alcohol use is a significant global health burden and is 
estimated to contribute to 2.5 million deaths worldwide each year (World Health 
Organization 2011).   Family, twin and adoption studies consistently suggest that 
genetic factors strongly influence the risk for AD.  AD is a dichotomous clinical 
diagnosis, defined by the fourth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) as the presence of 3 of the following 7 symptoms over the 
same period of 12 months: inability to quit drinking, drinking more than intended, 
withdrawal, spending excessive amounts of time related to drinking, tolerance, negative 
consequences of drinking on social, work and recreational activities and finally, 
continued drinking despite negative consequences (American Psychiatric Association 
2000).  Although the literature supports the role of genetic variation in the etiology of 
AD, identification of specific genes contributing to the development and maintenance of 
AD has proven difficult. These difficulties are due in part to the complex etiology of this 
pathological behavior and the likely contribution to risk for AD from numerous genes in 
multiple distinct pathways and networks.  An analysis of the genetic epidemiology of AD 
and the complexity of the AD phenotype highlights the diverse and complicated nature 
of its genetic risk factors. 
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Part I: The genetic epidemiology of AD 
Family, Adoption, and Twin Studies 
AD runs in families.  Early studies documented that alcoholics were more likely to 
have alcoholic family members in comparison to non-alcoholics or the population 
(reviewed in (Cotton 1979)).  Possible hypotheses for the transmission of the disease 
included both heritable and environmental risk.  Multiple reports looking at adopted male 
children of alcoholics provided evidence for genetic susceptibility for AD and alcohol 
abuse as these males had increased rates of AD even though removed from their 
alcoholic family environment (Goodwin, Schulsinger et al. 1973, Cloninger, Bohman et 
al. 1981, Sigvardsson, Bohman et al. 1996, Cadoret, Troughton et al. 1987).  Other 
studies examined the rates of alcoholism in female and male adoptees and found 
correlations between alcohol abuse in the adoptees and problem drinking (Cadoret, 
O'Gorman et al. 1985) or alcoholism (Bohman, Cloninger et al. 1987) in the biological 
parents. 
Twin studies can investigate phenotypes of interest and partition variance into 
shared environmental, common environmental and genetic components (Young-Wolff, 
Enoch et al. 2011).  Such studies repeatedly estimate the heritability for AD at around 
50%, suggesting approximately equal inputs from genetic and environmental risk factors 
(Heath, Bucholz et al. 1997, Hrubec, Omenn 1981, Kendler, Heath et al. 1992, McGue, 
Pickens et al. 1992, Kendler, Prescott et al. 1997, Pickens, Svikis et al. 1991, Prescott, 
Caldwell et al. 2005, Reed, Page et al. 1996, Romanov, Kaprio et al. 1991, Kalsi, 
Prescott et al. 2009, Prescott, Aggen et al. 1999, Prescott, Kendler 1999).  Though long 
noted that AD runs in families, and in children of alcoholics adopted by other families, 
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twin studies provided the first statistical estimates of the genetic contribution to the risk 
of AD.  A number of different approaches have been used to elucidate the genes 
underlying this risk. 
 
Linkage studies 
Linkage analysis investigates markers across the genome to locate chromosomal 
regions segregating within families in affected (but not unaffected) individuals with the 
phenotype of interest (Hirschhorn 2005).  There are numerous published linkage studies 
for AD and related phenotypes.  Table 1.1 summarizes linkage studies in the literature 
with published LOD scores >2.  In a 2009 review, Li and Burmeister (Li, Burmeister 
2009) noted that chromosomes 2, 4, 5, 7, 9, 10 and 13 had either significant (LOD > 
3.6) or suggestive (LOD between 2.2 and 3.6) peaks related to alcoholism (Lander, 
Kruglyak 1995).  Major linkage studies for AD have been performed on Mission Indian 
and Southwest American Indian tribes from the United States (Ehlers, Gilder et al. 2004, 
Long, Knowler et al. 1998), multiplex families in the Pittsburgh area (Hill, Shen et al. 
2004), the University of California, San Francisco  family alcoholism study (Gizer, Ehlers 
et al. 2011), the Collaborative Study on the Genetics of Alcoholism (COGA) (Reich, 
Edenberg et al. 1998, Foroud, Edenberg et al. 2000, Corbett, Saccone et al. 2005), the 
Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) (Prescott, Sullivan et 
al. 2006) and a four site study in the United States ((Panhuysen, Kranzler et al. 2010); 
European American subset and (Gelernter, Kranzler et al. 2009); African American 
subset).   
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Table 1.1.  Survey of Published Linkage Studies with LOD scores >2. 
 
 
 
 
Study Phenotype Sample (n)
Corbett, 2005 AD COGA (1464 families)
Foroud, 2000 AD COGA (262 families)
Gelernter, 2009 AD US/African American (238 families)
Gizer, 2011 AD UCSF (556 probands, 1080 1st deg relatives)
Hill, 2004 AD Pittsburgh (330 ppl)
Long, 1998 AD Southwestern American Indians (172 sib pairs)
Panhuysen, 2005 AD US/Europ. American (95 families)
Prescott, 2006 AD Irish (474 families)
Reich, 1998 AD COGA (105 families)
Bergen, 2003 Max. alcohol consumption Framingham Heart Study (2849 ppl)
Dick, 2002 Quantitative alcohol-related COGA (262 families)
Ehlers, 2004 Drinking severity Mission Indians (243 ppl)
Withdrawal Mission Indians (243 ppl)
Ehlers, 2005 Alcohol craving Mission Indians (885 ppl)
Ehlers, 2010 Initial sensitivity American Indians (381 ppl)
Foroud, 1998 Severe drinking COGA (105 families)
Gizer, 2011 Severe drinking symptoms UCSF (556 probands, 1080 1st deg relatives)
Kuo, 2006 Age of AD onset Irish (474 families)
Initial sensitivity Irish (474 families)
Tolerance Irish (474 families)
Withdrawal Irish (474 families)
Ma, 2003 Alcohol Consumption Framingham Heart Study (329 families)
Prescott, 2006 AD symptoms Irish (474 families)
Saccone, 2000 Max. alcoholic drinks COGA (370 families, 2263 sibpairs)
Schuckit, 2001 LR to alcohol COGA (745 ppl)
Schuckit, 2005 LR to alcohol COGA (238 sibpairs)
Webb, 2011 LR to alcohol Connecticut (238 sibpairs)
Wilhelmsen, 2003 LR to alcohol California (139 sibpairs)
Zhu, 2005 ALDX1 affected COGA (119 families)
 5 
 
Linkage studies have also examined a range of quantitative traits related to 
alcoholism including consumption (Ma, Zhang et al. 2003), maximum number of drinks 
in a twenty-four hour period (Saccone, Kwon et al. 2000, Bergen, Yang et al. 2003, Kuo, 
Neale et al. 2006), alcohol craving (Ehlers, Wilhelmsen 2005), initial sensitivity (Kuo, 
Neale et al. 2006, Ehlers, Gizer et al. 2010), level of response to alcohol (Wilhelmsen, 
Schuckit et al. 2003, Schuckit, Wilhelmsen et al. 2005, Webb, Lind et al. 2011, Schuckit, 
Edenberg et al. 2001), severe drinking (Foroud, Bucholz et al. 1998, Gizer, Ehlers et al. 
2011), age of AD onset (Kuo, Neale et al. 2006), alcohol withdrawal (Kuo, Neale et al. 
2006) and a quantitative alcohol-related phenotype (Dick, Nurnberger et al. 2002).   
 Overall, there is little consistency between studies and linkage signals are weak, 
in keeping with results from other complex traits. The inability of linkage analyses to 
locate genetic risk loci for AD is likely due to insufficient samples sizes to detect 
numerous, small effects and also the heterogeneous nature of the AD phenotype.   
Despite these difficulties, the IASPSAD linkage study of AD-related phenotypes and AD 
symptom count identified two chromosomal regions with substantial overlap with  
previous studies.  The first region, on chromosome 1, was linked to initial sensitivity and 
tolerance and will be discussed in detail in Chapter Four.  The second region, 
chromosome 4q22–q32, was found in a linkage study of AD symptom count and had a 
maximum LOD score of 4.59 (Prescott, Sullivan et al. 2006).  Seven other linkage 
studies (from three samples) of AD and related phenotypes have found evidence of 
linkage to the same chromosomal region.  The first sample, comprised of Southwest 
Indian tribes, found linkage with AD (Long, Knowler et al. 1998) while the second, 
comprised of Mission Indian tribes, found linkage with AD severity (Ehlers, Gilder et al. 
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2004).  The third, and largest, sample is COGA.  At least partial overlap of linkage 
signals was found with AD (Williams, Begleiter et al. 1999), AD symptom count (Reich, 
Edenberg et al. 1998), AD severity (Corbett, Saccone et al. 2005), maximum drinks 
(Saccone, Kwon et al. 2000) and an anxiety/AD clinical phenotype (Dick, Nurnberger et 
al. 2002).   Among the plausible candidate genes in this region is the ADH gene cluster, 
a well-recognized candidate gene cluster that has been frequently targeted in candidate 
gene association studies. 
 
Candidate Gene Association Studies 
As reported by Risch and Merikangas, association studies have superior power 
to detect genes underlying complex traits than linkage studies (Risch, Merikangas 
1996).   In contrast to linkage studies, association studies typically look within 
populations, not families, and currently focus on single nucleotide polymorphisms 
(SNPs).  Association studies for alcohol dependence have focused on the obvious 
metabolic and neurotransmitter candidate genes.  Due to the magnitude of literature 
related to this area, a brief overview of the most replicable and biologically relevant 
literature is included below. 
 
Candidate Genes - Alcohol metabolizing enzymes 
Ethanol is metabolized by three main enzymes (and obvious candidate genes for 
AD): alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH) and cytochrome 
P450 (CYP2E1).  In the cytoplasm, ADH catalyzes the reaction whereby ethanol is 
oxidized, producing the toxic compound, acetaldehyde (Berg, Tymoczko et al. 2002).  
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ALDH then catalyzes the detoxification/oxidation of acetaldehyde in the mitochondria 
(Agarwal 2001).  CYP2E1 encodes the major enzyme in an alternative pathway for 
ethanol metabolism in microsomes (Agarwal 2001).  A brief discussion of the most 
relevant variants of each gene is included below. 
Seven genes code for human ADH: ADH1A (formerly ADH1), ADH1B (formerly 
ADH2), ADHIC (formerly ADH3), and ADH4-7.  They cluster on chromosome 4q and 
are divided into five classes based on their protein sequence and rate of metabolism 
(Edenberg 2007).  Class 1 ADH enzymes, the primary ADH enzymes in the liver (Berg, 
Tymoczko et al. 2002), are dimers formed from combinations of α, β and γ polypeptides 
(encoded by the loci ADH1A, ADH1B and ADH1C, respectively) (Agarwal 2001).  Of the 
three variants of ADH1B, ADH1B*2 and ADH1B*3 are considered “protective”, having 
much higher rates of ethanol metabolism than ADH1B*1 (Edenberg, Xuei et al. 2006).  
In a study of Native American Mission Indians with AD, there was increased frequency 
of the ADH1B*1 variant (Wall, Carr et al. 2003). The higher rate of metabolism seen 
with the *B2 and *B3 alleles increases the production of the toxin acetaldehyde (Osier, 
Pakstis et al. 1999) and is considered to be aversive to further drinking (Bierut, Goate et 
al. 2012).  ADH1B*2 is found with greater frequency in Asian cultures (Shen, Fan et al. 
1997) but has also been reported as protective in white Europeans (Borras, Coutelle et 
al. 2000), African and European Americans (Bierut, Goate et al. 2012) and an Australian 
twin sample (Macgregor, Lind et al. 2009).  ADH1B*3 is associated with decreased risk 
for AD in Afro-Trinidadians (Moore, Montane-Jaime et al. 2007).    
ALDH has two human isozymes: ALDH1 and ALDH2.  While ALDH1 resides in 
the cytoplasm, variation exists in ALDH2, the fast-acting mitochondrial isozyme of ALDH 
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(Gemma, Vichi et al. 2006).   ALDH2 is encoded on human chromosome 12 and the 
single nucleotide transition that encodes the ALDH2*2 variant ablates enzymatic activity 
(Higuchi, Matsushita et al. 2004).  This allele is also prevalent in Asian populations and 
results in a flushing reaction and aversion to alcohol (Gemma, Vichi et al. 2006, Li, Zhao 
et al. 2012).  Studies have shown this allelic variant reduces the risk of AD in non-Asian 
populations as well (Luo, Kranzler et al. 2006) while other studies have shown the 
variant has no association with AD (Dickson, James et al. 2006).   
Typically functioning after heavy drinking has saturated ADH, CYP2E1 also 
metabolizes ethanol (Gemma, Vichi et al. 2006).  The CYP2E1 gene has thirteen 
polymorphisms: CYP2E1*1A-D, CYP2E1*2-4, CYP2E1*5A-B, CYP2E1*6 and 
CYP2E1*7C (Agarwal 2001).  Several of the variants show association with AD or 
related phenotypes.  CYP2E1*1B was reported to be more frequent in Mexican Indian 
alcoholics compared to controls (Montano Loza, Ramirez Iglesias et al. 2006). 
CYP2E1*6 was associated with AD in a Japanese sample (Iwahashi, Ameno et al. 
1998).  The CYP2E1*1D allele results in greater enzyme activity after alcohol 
consumption (McCarver, Byun et al. 1998)  and may contribute to the risk for alcohol 
and nicotine dependence (Gemma, Vichi et al. 2006).  A combined linkage and 
association study found significant association between level of response to alcohol and 
the CYP2E1*5B allele (Webb, Lind et al. 2011, Schuckit, Wilhelmsen et al. 2005, 
Wilhelmsen, Schuckit et al. 2003).  However, multiple studies have found no association 
between CYP2E1 variants and AD or related phenotypes (e.g. (Plee-Gautier, Foresto et 
al. 2001, Carr, Yi et al. 1996)).  While representing an obvious biological mechanism for 
involvement in AD, and providing strong association results (in particular in Asian 
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populations), variants in ethanol metabolizing enzymes fail to explain a large portion of 
the variance in AD in most populations. 
 
Candidate Genes - Gamma-Aminobutyric Acid 
Many behavioral consequences of alcohol use have been linked to the brain’s 
main inhibitory neurotransmitter, gamma-Aminobutyric acid (GABA).  There are two 
GABA receptor classes, GABAA and GABAB, with the former being implicated in 
behavioral responses to ethanol (Siegel, Agranoff et al. 1999, Kumar, Porcu et al. 
2009).  Mammalian GABAA receptors are heteropentamers formed from 19 possible 
subunits: α1–6, β1–4, γ1–4, δ, ε and ρ1–3
 (Siegel, Agranoff et al. 1999, Barnard, Skolnick et 
al. 1998).  GABRA1, GABRA6, GABRB2, and GABRG2 cluster on human chromosome 
5q (Dick, Edenberg et al. 2005).  Multiple groups have found AD to be associated with 
genes in this cluster (Luo, Kranzler et al. 2006, Sander, Ball et al. 1999) yet other 
groups find no associations with AD (Dick, Edenberg et al. 2005, Dick, Plunkett et al. 
2006, Song, Koller et al. 2003).   Overall, the literature provides conflicting results for 
associations between GABA and AD.  
One exception is seen with GABRA2 variants, which are among the best 
replicated genes in the candidate gene literature.  Positive association results between 
GABRA2 variants (human chromosome 4p) and AD are found in the COGA sample 
(Edenberg, Dick et al. 2004), a large case-control study of European Americans 
(Covault, Gelernter et al. 2004), Japanese men (Roh, Matsushita et al. 2011), German 
AD inpatients (Fehr, Sander et al. 2006, Soyka, Preuss et al. 2008) and a meta-analysis 
of 8 studies and 14 GABRA2 variants (Zintzaras 2012).  Recently, Olfson and Bierut 
 10 
 
compiled a list of fifty-four candidate genes for AD from the literature (including ADH1B, 
ALDH2 and CYP2E1) and looked for replication in the Study of Addiction: Genetics and 
Environment (SAGE) genome-wide association dataset  The only gene that was 
associated with AD was GABRA2 (Olfson, Bierut 2012). 
 
Candidate Genes - Dopamine 
It is thought that the reward circuitry in the brain contributes to the etiology of 
addiction.  The reward pathway and addiction will be discussed in Chapter Two. Briefly, 
alcohol increases the amount of dopamine (the major neurotransmitter in the reward 
pathway) in areas of the brain important in the learned anticipation of reward (Ron, Jurd 
2005).  For this reason, genes involved in dopamine neurotransmission have been 
studied as candidates for AD.  There are five known human receptor subtypes for 
dopamine, D1-D5, located on chromosomes 5,11,3,11 and 4, respectively (Siegel, 
Agranoff et al. 1999).  D3 and D4 receptor subtypes are typically not associated with AD 
in the literature (Parsian, Chakraverty et al. 1997, Gorwood, Martres et al. 1995), 
although at least one study found DRD3 to be associated with AD in a Caucasian 
sample (Hack, Kalsi et al. 2011).  The D2 receptor subtype has been extensively 
investigated but the literature remains complicated.  For example, Goldman et al found 
association with the D2 receptor subtype (Goldman, Urbanek et al. 1997), but the 
results failed to replicate in two subsequent studies (Gelernter, Kranzler 1999, Lee, Lu 
et al. 1999).  The dopamine transporter gene, DAT1, has also been frequently studied.  
The most investigated polymorphism is a variable number of tandem repeats in the 
3’UTR of the gene.  As reviewed in van der Zwaluw et al, most studies have found little 
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association with AD, but some association with alcohol withdrawal (van der Zwaluw, 
Engels et al. 2009).  Other positive results within DAT1 include associations between 
rs6350, an exonic SNP, and both alcohol consumption (Lind, Eriksson et al. 2009) and 
AD (Hack, Kalsi et al. 2011).   
As is exemplified in the association findings with dopamine and related genes, the 
candidate gene literature for alcoholism is full of false positives, conflicting reports, and 
sample-limited findings.  In order to elucidate the genetic risk loci for AD, refined or new 
approaches are needed. Options for uncovering the missing heritability include better 
methods for candidate gene selection (to be covered in Chapter Two) and an unbiased 
method for locating new candidates. 
 
Genome-wide Association Studies 
The advantage of linkage studies is that they allow for an unbiased, genome-
wide search for candidate genes.  Association studies have superior power to detect 
genes for complex traits and map candidate genomic regions more tightly than linkage 
studies.  Recently, advances in genotyping technology enabled genome-wide 
association studies (GWAS).  Using GWAS, researchers can, without bias, identify fine-
mapped areas of the genome associated with complex traits.  GWAS involve 
genotyping individuals at SNPs, single base pair changes that occur in DNA, throughout 
the genome.  Large-scale sequencing efforts such as The Human Genome project 
(Lander, Linton et al. 2001) and 1000 Genomes Project (1000 Genomes Project 
Consortium 2010) have contributed to the over 30 million validated SNPs in the latest 
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/).  SNPs can be in linkage 
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disequilibrium (LD) with other SNPs, meaning that two SNPs are associated more often 
than would be expected by chance alone.  Two SNPs in high LD carry information about 
each other; that is by knowing information about one SNP you can predict information 
about the second SNP.  The International Hapmap project has genotyped individuals 
from distinct ancestries (such as Northern and Western European or Han Chinese) 
allowing researchers to examine LD in each population (International HapMap 
Consortium 2003).  By examining LD and haplotypes, or groups of alleles that are 
transmitted together, one can reduce the number of SNPs necessary to explain 
maximum information about the genome.  Current GWAS arrays genotype 
approximately one million SNPs per individual.   
To date, there have been eleven published GWAS which examine AD, two 
GWAS of AD symptoms and one small-scale meta-analysis. Six of those studies 
reported genome-wide significant findings after correction for multiple testing.  Treutlein 
et al performed a GWAS in a German case-control sample and found significant 
association with two SNPs on chromosome 2: rs7590720 (intronic to PECR) and 
rs1344692 (intronic to AK093362) (Treutlein, Cichon et al. 2009).  A second German 
case-control GWAS reported association with rs1789891, a SNP in LD with ADH1C 
(Frank, Cichon et al. 2012).  The third study, comprised of predominately Caucasians, 
found several SNPs associated within KIAA0040 (Zuo, Zhang et al. 2012).  Fourth, a 
small-scale meta-analysis by Wang and colleagues also found significant association in 
KIAA0040 and a second gene, THSD7B (Wang, Liu et al. 2011).  The fifth study tested 
for association in the COGA sample and an Australian sample and found multiple SNPs 
associated within DSCAML1 (Wang, Liu et al. 2011).  Finally, SNPs within C15orf53 
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were significantly associated with AD symptom count in the COGA families (Wang, 
Foroud et al. 2012). The remaining eight GWAS reported no genome-wide significant 
findings (Bierut, Agrawal et al. 2010, Edenberg, Koller et al. 2010, Heath, Whitfield et al. 
2011, Lind, Macgregor et al. 2010, Zuo, Zhang et al. 2012, Zuo, Zhang et al. 2011, 
Kendler, Kalsi et al. 2011, Dickson, James et al. 2006).   Within the AD GWAS 
literature, PKNOX2 has shown some evidence for replication. In the SAGE GWAS, the 
top SNP, though not genome-wide significant, was intronic to PKNOX2 (Bierut, Agrawal 
et al. 2010).   Wang et al used a subset of the Australian twin-family study of alcohol 
use disorder (OZALC) GWAS sample and also found significant, though not genome-
wide, association with SNPs within the gene (Wang, Liu et al. 2011). 
In addition to GWAS of AD, multiple GWAS reports of alcohol-related phenotypes 
have been published.  These are summarized in Table 1.2.  Of those, there are three 
reports of genome-wide significant SNPs, all associated with alcohol consumption.   
Takeuchi and colleagues found association with rs671 (in ALDH2) in a Japanese cohort 
(Takeuchi, Isono et al. 2011).  Looking within a Korean sample, Baik et al found 
association in SNPs within 6 genes; c12orf51, CCDC63, MYL2, OAS3, CUX2, and 
RFH3A (Baik, Cho et al. 2011).  SNPs within c12orf51 were also in LD with ALDH2. 
Lastly, a large, predominately Caucasian GWAS reported significant association of 
rs6943555 in AUTS2 (Schumann, Coin et al. 2011). The remaining GWAS presented in 
Table 2 reported no genome-wide significant results (Agrawal, Wetherill et al. 2012, 
Chen, Xiong et al. 2012, Heath, Whitfield et al. 2011, Wang, Liu et al. 2012). There were 
no replicated SNPs or loci among the top results in these studies. 
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Table 1.2. Survey of Published GWAS for AD-related Phenotypes. 
 
 
 
 
 
Refined GWAS methodology 
A review of the GWAS literature for AD and related phenotypes shows a minimal 
number of genome-wide significant results and few replicated loci.  Association studies 
are based on the common disease - common variant (CDCV) hypothesis; that there are 
a large number of loci of small effect size that contribute to risk for AD (Rowe, Tenesa 
2012). Threshold approaches looking only at SNPs that pass an a priori significance 
level may leave researchers vulnerable to reporting false positives while also missing 
true association signals.   
 
Refined GWAS methodology - FDR control 
One simple technique to explore a larger number of variants is the false 
discovery rate (FDR) procedure. The FDR approach attempts to limit the number of 
Study Phenotype Study Type Primary sample size
Baik, 2011 Alcohol consumption Population 1721 males  
Schuman, 2011 Alcohol consumption Population 26,316 individuals
Takeuchi, 2011 Alcohol consumption Population 1462 individuals                       
Agrawal, 2012 Alcohol craving Ascertained 1899 AD cases, 1938 controls
Chen, 2012 Alcohol drinking Population 904 individuals
Heath, 2011 Alcohol drinking Ascertained 6852 individuals
Wang, 2012 Alcohol withdrawal symptoms Ascertained 461 cases, 408 controls
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false negatives while allowing for a few false positives, attempting to ensure that truly 
significant results are not overlooked (Benjamini, Hochberg 1995).  Within each dataset, 
a FDR value (q-value) is empirically set as a cutoff point.  A q-value of 0.2, for example, 
is interpreted as 20% of the p-values at that level or more significant representing false 
positives.  Therefore, p-values whose associated q-values are more significant than the 
appointed cutoff are statistically more likely to be true risk variants (Neale, Ferreira et al. 
2008).  Using a FDR control allows for a larger set of results to be analyzed, which may 
represent true association signals lost in the noise of large association studies. 
As proof of principle, a FDR approach was used in a recent, unpublished GWAS 
of AD in the IASPSAD sample with positive results (Hack et al, unpublished).   Only two 
SNPs passed the a priori significance threshold of 3.06 x 10-8.  However, using a FDR 
q-value < 0.2, twenty-six other loci were identified as associated with AD.   Mutations in 
at least two of the loci have previous associations with alcohol-related phenotypes in 
model organisms: RYR3 and KLF2.  These results would have been missed by just 
considering the top, genome-wide significant results. 
 
Refined GWAS methodology – Gene-based association 
A second technique to avoid the threshold approach is to use gene-based or 
pathway analyses.  Gene-based association studies begin by assigning SNPs to genes 
and then typically use either the minimum p-value per gene (e.g., (Bigdeli, Maher et al. 
2011)) or a combination of all p-values (e.g., using the Simes procedure (Li, Gui et al. 
2011)  or Fisher’s combination test (Curtis, Vine et al. 2008)).  In Bigdeli et al and Li et 
al, the gene-based approach identified more significantly associated variants than 
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individual SNP association tests.  Using one SNP per gene cannot test if modest 
associations in multiple variants within a gene are significantly related to the phenotype 
of interest.  Techniques using multiple SNPs per gene are an improvement, however 
they do not take into account LD.  If multiple associated SNPs are in LD, using all of 
them will artificially inflate the test statistic.  
The Versatile Gene-Based Test for GWAS (VEGAS) assigns SNPs to genes, 
accounts for LD through a series of Monte Carlo simulations and calculates an empirical 
gene-based test statistic for each gene (Liu, McRae et al. 2010).  To date, this is the 
best option for gene-based association as it combines the use of multiple variants per 
gene while also taking into account the LD between SNPs.  Unpublished results from a 
GWAS of maximum alcohol consumption in the IASPSAD sample (Chapter Five) 
identified a gene using VEGAS with multiple previous associations with addiction, 
alcohol consumption and neuroadaptation following chronic alcohol use.  No single 
SNPs from this candidate gene were within the top results.  
 
Refined GWAS methodology –Pathway analyses 
Pathway analyses look for modest associations, in aggregate, among genes in a 
predefined pathway.   These methods allow researchers to look for overrepresentation 
of association signals in either large groups of genes forming a functional pathway or in 
a hand-picked gene list.  A disadvantage, compared to the gene-based association 
analyses, is that these methods rely on pre-defined gene pathways.  The researcher is 
testing GWAS data for groups of genes already known to be functionally related.  
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Uncharacterized loci that might contribute to a phenotype of interest would therefore be 
missed.   
One popular pathway analysis method is Association LIst Go AnnoTatOR 
(ALIGATOR) which examines SNP association in gene sets defined by Gene Ontology 
(GO) and tests whether the number of genes significantly associated in each set is 
greater than the number expected by chance (Holmans, Green et al. 2009).  GO is a 
database that collects and organizes information regarding gene products’ biological, 
cellular and molecular aspects (Ashburner, Ball et al. 2000).   A recent GWAS of 
information processing speed found no genome-wide significant associations with single 
SNPs but several biological pathways associated with related traits after using 
ALIGATOR (Luciano, Hansell et al. 2011).  
Other pathway analyses can input a user-defined set of genes and test for 
association of SNPs, in aggregate, in these genes compared to a random gene list.  
Gene Set Enrichment Analysis (GSEA), originally developed for microarrays 
(Subramanian, Tamayo et al. 2005), has been modified for GWAS data (Wang, Li et al. 
2007).  SNPs are assigned to genes, each gene is represented by the minimum p-
value, and an enrichment score is calculated by comparing the number of positive 
associations in the predefined gene set with a random gene set.  FDR, gene-based and 
pathway-based analyses allow researchers to examine their data in ways not possible 
with single SNP association. Oftentimes these methods reveal new candidate genes or 
pathways for phenotypes of interest. 
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Part II: A brief overview of the phenotypic complexity of AD 
As discussed previously, alcohol dependence (AD) is a dichotomous, broad and clinical 
diagnosis. Two individuals can meet diagnostic criteria for AD with different symptoms.  
Furthermore, there are many different risk pathways for AD.  Pathways to AD include 
physiological traits that affect how an individual processes and reacts to ethanol.  They 
also include co-occuring or predisposing psychiatric conditions such as depression.  
Examining AD as a phenotype is useful to test variants for risk to a broader liability for 
alcohol use problems.  However, breaking the phenotype down into individual 
components of risk is a powerful methodology.  Two risk pathways for AD are explored 
in this dissertation: physiological alcohol-related phenotypes and internalizing 
psychopathology. 
 
Alcohol-related phenotypes 
Researchers have had modest success finding genes associated with AD, but 
analyzing alcohol-related phenotypes (ARPs) is an attractive alternative.  ARPs are 
specific factors thought to contribute to the overall risk for AD.  While AD is likely due in 
part to the action of numerous genes, ARPs, like physiological measurements, may be 
closer to the underlying genetic risk factors, may be localized to specific regions of the 
genome and are more likely to comprise smaller gene networks.  The linkage and 
GWAS sections of this Introduction have presented results from both the AD analyses 
and those of ARPs such as level of response to alcohol, alcohol consumption, tolerance 
and withdrawal.  Chapters Four and Five present an in-depth review of two ARPs. 
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Comorbidity 
Comorbidity is the norm rather than the exception in common psychiatric (e.g. 
major depression) and substance use disorders (e.g. alcohol dependence)(Kessler, 
Nelson et al. 1996, Regier, Farmer et al. 1990).  Internalizing disorders, characterized 
by negative mood states, include major depression, dysthymia, generalized anxiety 
disorder and phobias. Externalizing disorders, characterized by acting out and 
behavioral disinhibition, include substance use disorders, adult antisocial personality 
disorder and conduct disorder.  AD correlates most strongly with the externalizing 
disorders, but is significantly correlated with internalizing disorders as well (Kessler, 
Nelson et al. 1996, Kessler, Crum et al. 1997, Kessler, Chiu et al. 2005, Regier, Farmer 
et al. 1990, Dawson, Goldstein et al. 2010).  In concert with ARPs, it is only by 
understanding the relationship between AD and comorbid phenotypes, and the genetic 
architecture contributing to each, that researchers can begin to untangle the genetics of 
alcohol use disorders.  Chapter Six discusses these concepts in detail and presents 
ongoing work in examining the relationship between AD and comorbid internalizing 
disorders.   
 
Conclusion 
A strong foundation of evidence supports the existence of genetic risk factors for 
AD and related phenotypes.  Past and current methodologies have uncovered few 
replicable genetic risk loci for AD and AD-related phenotypes.  This dissertation 
examines four different methods to uncover genetic risk factors for Alcohol 
Dependence. In Chapter Two, the model organism literature is used to provide a better 
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candidate gene selection method for alcohol-related traits in humans.  Chapter Three 
focuses on an early GWAS methodology to identify genes of interest and then 
subsequent analyses of the top results.  The final three chapters represent analyses in 
the genomics era of alcohol research.  Chapters Four and Five present results from 
GWAS studies of two quantitative traits known to influence risk for AD; initial sensitivity 
and maximum alcohol consumption in twenty-four hours. In Chapter Six, preliminary 
results from the creation of a multivariate AD/internalizing phenotype are presented in 
an effort to identify risk loci for a broader comorbid disease liability in GWAS data.   
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CHAPTER TWO 
 
Investigating the Role of GPSM1 in Human Alcohol Dependence and Craving 
Behaviors 
 
Introduction 
Among the many factors contributing to the high prevalence of Alcohol Dependence 
(AD) is the frequent endorsement of craving among high risk alcohol drinkers.  Even 
among individuals who undergo treatment, up to 60% will relapse within a year (Hunt, 
Barnett et al. 1971). Factor analyses consistently show craving loading highly onto the 
existing criteria for Alcohol Dependence (AD) as defined by the fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (Cherpitel, Borges et al. 
2010, Keyes, Krueger et al. 2011, Casey, Adamson et al. 2012, Agrawal, Wetherill et al. 
2012).  In part due to this evidence, the upcoming DSM-V will include craving in the AD 
diagnosis, defined as the ‘strong desire or urge to use’ alcohol (dsm5.org).   
 
The biology of craving 
To discuss the proposed biology of craving, it is necessary to briefly introduce 
both Koob’s theory of addiction and the brain’s reward system.  A prominent theory 
developed by Koob explains addiction as hedonic homeostatic dysregulation (Koob, Le 
Moal 1997).  He describes addiction as a cycle of dysregulation in the brain’s reward 
system.  In the case of alcohol addiction, individuals would initially drink to receive 
pleasurable effects but eventually end up drinking to avoid the negative consequences 
associated with withdrawal. This was termed counteradaptation and is based on the 
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opponent-process theory (Solomon 1980). The other main tenant of Koob’s theory is 
sensitization.  Sensitization, seen as the increasing effect of a drug of abuse after 
repeated use, results in a hypersensitive brain reward system (Koob, Le Moal 1997). 
Counteradaptation and sensitization therefore together contribute to drug-seeking and 
eventual addiction (Koob, Le Moal 1997).  Changes in the brain after repeated drug 
exposure, or imbalances during withdrawal, are loosely termed neuroadaptations (Anton 
1999).  
Alcohol increases the amount of extracellular dopamine in the mesolimbic 
dopaminergic pathway, the main component of the brain’s reward system (Ron, Jurd 
2005).  Dopaminergic neurons project from the ventral tegmental area to the nucleus 
accumbens, amygdala and other regions of the basal forebrain (Nestler 2001).  Aside 
from the nucleus accumbens, a region implicated in the learned anticipation of reward, 
the basolateral amygdala and extended amygdala are integral in reward processing 
(Koob 2006).  The basolateral amygdala is thought to contribute to relapse by its 
integration of drug-related memories and stress (Belujon, Grace 2011), resulting in cue-
induced craving (Koob 2006).  Part of the extended amygdala, the central nucleus of the 
amygdala is involved in drug-reinforcement, integrating stimuli as positive (incentive 
salience) or negative (aversive salience) (Koob 2006, Ode, Winters et al. 2012).  As 
mentioned earlier, Koob’s model of addiction suggests that sensitization results in 
hypersensitive mesolimbic dopamine system and this is thought to manifest itself as 
craving (Anton 1999).   
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The genetics of craving 
The heritability of craving has been estimated to be 65% (Ehlers, Wilhelmsen 
2005).  Multiple genetic risk loci for craving have been reported in the literature including 
SRD5A2 (Lenz, Schopp et al. 2012), AR and CYP19A1 (Lenz, Jacob et al. 2009, Lenz, 
Heberlein et al. 2011), NK1R (Seneviratne, Ait-Daoud et al. 2009), SCNA (Bonsch, 
Greifenberg et al. 2005, Bonsch, Reulbach et al. 2004, Foroud, Wetherill et al. 2007), 5-
HTTLPR (Bleich, Bonsch et al. 2007), GABRA6 (Han, Bolo et al. 2008), TACR1 (Blaine, 
Claus et al. 2012) and dopamine D2 receptors (Heinz, Siessmeier et al. 2005). 
Recently, Agrawal et al performed a genomewide association study (GWAS) of craving 
(Agrawal, Wetherill et al. 2012).  No single nucleotide polymorphisms (SNPs) were 
genomewide significant.  The top hit, rs2454908, was located on chromosome 7 within 
ITGAD.   
Model organism studies of addiction and withdrawal have implicated GPSM1, or 
AGS3, and drug-seeking behavior.  GPSM1, G protein signaling modulator 1, encodes 
a guanine dissociation inhibitor located on the long arm of human chromosome 9 
(9q34.3).  The rodent ortholog of GPSM1, Ags3, has been previously implicated in 
morphine withdrawal (Fan, Jiang et al. 2009) and cocaine- (Bowers, McFarland et al. 
2004) and heroin- (Yao, McFarland et al. 2005) seeking during withdrawal.  Of particular 
interest, Bowers and colleagues investigated differential protein expression of Ags3 and 
ethanol-seeking in rats (Bowers, Hopf et al. 2008).  Briefly, rats taught to self-administer 
ethanol showed correlated increases in both ethanol-seeking behavior and expression 
of Ags3 in the nucleus accumbens after 3 weeks of ethanol withdrawal. RNAi 
knockdown of Ags3 diminished ethanol-seeking behavior.  This increase in Ags3 
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expression seen in the rodent model during withdrawal may represent a 
neuroadaptation which occurs during periods of abstinence after heavy alcohol use.   
This chapter presents work investigating the role of GPSM1 in humans.  SNPs 
within GPSM1 were genotyped in the Irish Affected Sib Pair Study of Alcohol 
Dependence (IASPSAD) sample and tested for association with AD and craving related 
behaviors.  Replication was sought in another ascertained sample, the Collaborative 
Study on the Genetics of Alcoholism (COGA). Finally, GPSM1 messenger RNA (mRNA) 
expression differences were tested in human chronic alcoholic and control post-mortem 
brain tissues.   
 
Methods 
Primary sample: Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) 
A detailed description of the sample is provided elsewhere (Prescott, Sullivan et 
al. 2006).  Briefly, probands were ascertained in clinical treatment facilities and hospitals 
in the Republic of Ireland and Northern Ireland between 1998 and 2002.  Probands 
were interviewed using an adapted version of the Semi-Structured Assessment of the 
Genetics of Alcoholism (SSAGA) and diagnosed with AD using DSM-IV criteria.   The 
sample is ethnically homogenous; a stipulation for inclusion in the study required each 
proband have all 4 grandparents born in Ireland, Northern Ireland, Scotland, Wales or 
England.  Controls were recruited from the National Guard and army reserve in the 
Republic of Ireland and from volunteers donating at the Northern Ireland Blood 
Transfusion Service in Northern Ireland.  Controls had no reported history of alcoholism.  
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From the original linkage sample, 562 genetically independent AD cases and 569 
controls were selected for genotyping analyses.   
 
Replication sample: Collaborative Study on the Genetics of Alcoholism (COGA) 
Probands for the COGA sample, details of which are described elsewhere (Dick, 
Plunkett et al. 2006), were recruited throughout the United States in 6 geographic 
locations from alcohol treatment programs.  Large families were preferentially 
ascertained with a proband required to have 2 or more family members in the COGA 
sampling area and preferably sibships greater than 3.  All individuals were given the 
SSAGA interview and AD diagnosed using DSM-IV criteria. From the larger COGA 
sample, 847 genetically independent AD cases and 552 controls of European ancestry 
were used.   
 
Phenotypes  
Three phenotypes were analyzed in both samples: AD (DSM-IV), craving and a 
sum score. Craving was extracted from the SSAGA interview (“Do you have a strong 
desire to drink when you cannot?”) as a dichotomous variable.  The sum score 
phenotype was calculated by totaling how many of the following phenotypes a subject 
endorsed: craving (as above), DSM-IV AD Symptom 3 (“Have you started drinking when 
you promised yourself you would not or have you ever drunk more than you intended?”) 
and DSM-IV AD Symptom 5 (“Have you ever spent so much time drinking alcohol or 
recovering from it that you had little time for anything else?”).  Both DSM-IV Symptom 3 
and 5 were also extracted from the SSAGA interview as dichotomous variables. 
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SNPs and genotyping: IASPSAD 
SNPs were genotyped using monoplex genotyping.  Monoplex reactions were 
performed using Taqman Assays-on-Demand (Applied Biosystems, Foster City, CA, 
USA).  One SNP, rs28539249, was genotyped using a custom Taqman Assay 
(sequence available upon request).  Genotypes were called using the Analyst AD 
fluorescence detector (LJL Biosystems, Sunnyvale, CA, USA) and automated Excel 
template (van den Oord, Jiang et al. 2003).  To minimize technical variability, all 
reaction steps were performed using the Eppendorf 5075 automated liquid handler.  
Stringent evaluation of initial data is important to avoid artificial effects of genotyping 
errors; therefore, all genotypes were independently assessed by two raters. Ambiguous 
calls were discussed and in cases of non-resolution, genotypes were dropped from the 
analyses. 
 
SNPs and genotyping: COGA 
Genotypes for analysis were extracted from the COGA GWAS dataset.  As 
detailed elsewhere (Edenberg, Koller et al. 2010), COGA samples were genotyped on 
Illumina HumanHap1M Bead Chips (Illumina, San Diego, CA) by the Center for 
Inherited Disease Research (CIDR).   After stringent quality control measures, 853,375 
SNPs were available for analysis. The dataset was subsequently imputed with 
IMPUTE2 (Howie, Donnelly et al. 2009) using the March 2012 version (v3) of the 1000 
Genomes reference panel (1000 Genomes Project Consortium 2010).  SNPs were 
filtered for minor allele frequency (MAF) <1% and information content ≤3%. After 
filtering, 8.5 million SNPs remained.  
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Data analysis 
IASPSAD single marker association analyses and Hardy-Weinberg Equilibrium 
(HWE) testing were performed using Plink v1.07 
(http://pngu.mgh.harvard.edu/purcell/plink) (Purcell, Neale et al. 2007).  Logistic 
regression was performed on the IASPSAD case-control sample, with sex as a 
covariate.  Linear regression was performed on the AD cases in the IASPSAD sample, 
with sex and age as covariates.  SNPSpD (Nyholt 2004) was used to determine the 
number of independent of tests for multiple testing corrections.   Analysis with SNPSpD 
in the IASPSAD sample identified 5 independent SNPs, yielding an adjusted threshold 
of p<0.0091.  COGA single marker association analyses were performed using Plink 
v1.07 and the imputed dosages.  Within the case-control sample, SNPs were tested for 
association using sex as a covariate.  Craving and the sum score phenotypes were 
tested within cases using age and sex as covariates.  Phenotypic distributions are 
shown in Tables 2.1 and 2.2. 
 
 
 
Table 2.1. Phenotype distributions in the case-control analyses.  
 
 
 
Phenotype No. cases No. controls
IASPSAD AD 535 522
Craving 428 522
COGA AD 847 552
Craving 486 552
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Table 2.2 Phenotype distributions in the case-only analyses. 
 
 
 
 
Gene expression study: sample 
Superior frontal cortex (CTX), central nucleus of amygdala (CNA) and basolateral 
nucleus of amygdala (BLA) tissues from human chronic alcoholics and controls from the 
New South Wales Tissue Resource Centre (NSW TRC) located at the University of 
Sydney were used in this study.  As described in Ponomarev, 2012, DSM-IV diagnosis 
of cases was based on clinical review. A GWAS was performed on 41 chronic 
alcoholics and 41 cases from the NSW TRC using Affymetrix 6.0 arrays (Riley et al, 
unpublished results).  Expression data was available for 17 chronic alcoholics and 15 
controls from the NSW TRC from a genome-wide expression study with Illumina 
(Illumina, San Diego, CA) HumanHT-12 whole genome expression bead chips 
(Ponomarev, Wang et al. 2012).  The samples from these studies were not congruent, 
so the overlapping samples between the datasets, 12 chronic alcoholics and 8 controls, 
were chosen for analyses. 
 
         Craving     Sum Score
Yes No 0 1 2 3
IASPSAD 428 107 1 47 113 374
COGA 486 360 68 243 217 319
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Gene expression study: data analysis 
Sex, age, PMI (post-mortem interval), liver pathology, neuropathology, 
toxicology, brain pH, and smoking demographics were provided by the NSW TRC.  As 1 
out of the 20 samples was female, sex was not included as a covariate.  RNA integrity 
number (RIN) values were provided for each tissue, however a Fisher’s exact test was 
non-significant for differences between cases and controls in the CTX, CNA and BLA 
(p=0.586, 1, and 0.906, respectively).  RIN was therefore not included as a covariate.  
Liver pathology, neuropathology and toxicology were re-coded numerically for 
subsequent analyses.  Principal components analysis (PCA) was run in SASv9.3 using 
age, PMI, liver pathology, neuropathology, toxicology, brain pH, and smoking.  The first 
5 components explained 90% of the variance in the dataset (Figure 2.1).  Component 
scores for the first 5 components were used as covariates in the analyses.   
Differences in GPSM1 mRNA expression (Illumina identifier ILMN_1709307) 
between cases and controls were analyzed using the PROC GLM – MANOVA test in 
SAS.  The GWAS dataset (Riley et al, unpublished results) was imputed with IMPUTE2 
(Howie, Donnelly et al. 2009) using the March 2012 version (v3) of the 1000 Genomes 
reference panel (1000 Genomes Project Consortium 2010).  Association tests for allele-
specific expression differences were performed in Plink v1.07 with imputed dosages 
and using the aforementioned component scores as covariates.   
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Fig. 2.1.  Eigenvalues and scree plot results for principal components analysis. 
Age, PMI, liver pathology, neuropathology, toxicology, brain pH, and smoking 
demographics from 12 alcoholic cases and 8 controls were run in a PCA.  The first five 
components explained 90% of the variance. 
 
 
 
 
 
Eigenvalues of the Correlation Matrix: Total =7, Average =1
Eigenvalue Difference Proportion Cumulative
1 2.12699 0.70097 0.30390 0.30390
2 1.42603 0.19799 0.20370 0.50760
3 1.22804 0.34495 0.17540 0.68300
4 0.88309 0.24730 0.12620 0.80920
5 0.63580 0.19288 0.09080 0.90000
6 0.44292 0.18578 0.06330 0.96330
7 0.25714 0.03670 1
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Results 
Nine SNPs within GPSM1 were genotyped in the IASPSAD sample. Two SNPs 
genotyped poorly and were dropped.  No SNPs showed significant deviation from HWE 
(p < 0.001).  One SNP was removed for excessive missingness (19%). Seventy-four 
samples were removed for having more than 2 missing genotypes (>33% missingness).  
After data cleaning, a total of 6 SNPs were analyzed for tests of association on a 
possible 535 AD cases and 522 controls.   
One SNP, rs28626972, was nominally associated with AD in the IASPSAD case-
control sample but did not pass multiple testing correction (Table 2.3). No SNPs were 
significantly associated in the craving cases versus controls analysis.  Within AD cases, 
rs28439345 was nominally associated, only, with craving (Table 2.4). Rs28439345 and 
rs28536668 were nominally associated with the sum score phenotype and rs28439345 
remained significantly associated after multiple testing correction.   
 
 
Table 2.3. Association Results for GPSM1 in the IASPSAD and COGA case-
control samples.   
 
Nominal p-values are shown for association between each of the six SNPs within 
GPSM1 and two phenotypes: AD and craving. 
 
IASPSAD COGA
SNP BP AD Craving AD Craving
rs28380074 139225139 0.3900 0.5652 0.4320 0.5711
rs28626972 139227544 0.0427 0.1106 0.3919 0.6413
rs28536668 139234512 0.2131 0.5547 0.5458 0.8262
rs28439345 139243790 0.1860 0.6425 0.8309 0.4096
rs3812547 139252495 0.2432 0.2720 0.3909 0.9061
rs1128905 139253839 0.1008 0.2639 0.7814 0.9397
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Table 2.4.  Association Results for GPSM1 within IASPSAD and COGA AD cases.   
 
Nominal p-values are shown for association between each of the six SNPs within 
GPSM1 and two phenotypes: craving and a sum score calculated from endorsement of 
three possible craving-related behaviors. 
 
 
 
Based on the association results in our sample, we sought to replicate our 
findings in an independent sample.  Association results from the COGA case-control 
sample, and within the case-only analysis, are shown in Tables 2.3 and 2.4, 
respectively.  No SNPs were associated in the COGA case-control sample. Within 
COGA cases, rs28626972 remained associated with craving after a Bonferroni 
correction for the six tested SNPs (p=0.048).  Rs28439345, identified in the IASPSAD 
sample as associated with the sum score, was also significantly associated with the 
sum score phenotype within the COGA cases.   
We then examined GPSM1 mRNA expression in human postmortem brain 
tissues from the NSW TRC. There were no expression differences between cases and 
controls (MANOVA p=0.1831).  Allele specific expression differences (rs28439345) 
were tested in three brain regions: the basolateral nucleus of amygdala (BLA), central 
IASPSAD COGA
SNP BP Craving Sum Score Craving Sum Score
rs28380074 139225139 0.5866 0.6848 0.6754 0.1909
rs28626972 139227544 0.3098 0.0873 0.0080 0.6487
rs28536668 139234512 0.1696 0.0457 0.5022 0.3162
rs28439345 139243790 0.0188 0.0035 0.4459 0.0472
rs3812547 139252495 0.8304 0.7425 0.1853 0.3801
rs1128905 139253839 0.2583 0.1601 0.4853 0.7099
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nucleus of amygdala (CNA), and superior frontal cortex (CTX). No differences were 
found (p=0.716, 0.323 and 0.831, respectively). 
 
Discussion 
Relapse is a trademark of addiction. With all drugs of abuse, including alcohol, addicts 
are plagued by high rates of recidivism and difficulty remaining abstinent.  The 
phenotype seen in the rat model described by Bowers et al seems to approximate the 
compulsive, alcohol-seeking behavior seen in many chronic alcoholics during periods of 
withdrawal.  The report also implicated increased expression of GPSM1 in drug-seeking 
behavior during withdrawal.   Therefore, GPSM1 was examined in human AD using 
association and expression studies. 
A series of association analyses with AD and craving-related phenotypes was 
performed.  First, the broad diagnostic phenotype of AD was studied to ascertain if 
variation in GPSM1 distinguished AD cases from controls.  No SNPs survived multiple 
testing correction in the IASPSAD sample and no SNPs were nominally associated in 
the COGA sample.  All subsequent association analyses involved more specific 
phenotypes. There was no association in the case-control analysis of craving, 
suggesting that variation in the gene did not distinguish craving AD cases from controls.  
It was then asked if variation in GPSM1 distinguished cases endorsing craving from 
cases who did not report craving alcohol.  No SNPs survived multiple testing correction 
in the IASPSAD sample. Rs28626972 was significantly associated with craving within 
the COGA AD cases and remained significant after Bonferroni correction for the six 
tested SNPs.  Finally, it was determined that variation in GPSM1 was associated with a 
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sum score phenotype comprised of three craving-related behaviors.  Rs28439345 was 
associated with the sum score in the IASPSAD cases after multiple testing correction 
and was replicated in the COGA AD cases (p=0.047).  In both samples, the minor allele 
of the SNP was associated with decreased sum score, or a decrease in the craving-
related behaviors included in the analysis. 
Rs28439345 is intronic to GPSM1.  There are no known reported associations 
between this variant and alcohol-related phenotypes in the literature. To further 
investigate the role of GPSM1 and rs28439345 in human alcoholism, mRNA expression 
differences between chronic alcoholic and control post mortem amygdala and cortex 
tissues were examined.  There were no GPSM1 expression differences in any of the 
tested brain regions. Similarly, no allele-specific expression differences were seen.  
Further research is necessary to determine the effect of variation within GPSM1 on the 
queried phenotypes. 
There are three main limitations in this study.  First, the experimental paradigms 
used in the model organism studies are impossible to replicate in human samples.  
Secondly, an assumption is made that the ethanol-seeking behavior reported in rats in 
the literature is related to the craving behaviors investigated in both human samples.  
Finally, Bowers et al found protein expression differences while this study only 
examined mRNA expression.  It is possible that there are protein expression differences 
in our tissue samples while mRNA levels remain unchanged.  
This chapter has presented results showing variation within GPSM1 is 
associated with a craving sum score phenotype in two independent, clinically 
ascertained samples. This provides a link between human craving of alcohol and a 
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gene implicated in drug-seeking behavior in rodents.  Furthermore, this work suggests 
that the model organism literature provides a targeted, improved method for selection of 
candidate genes in addiction research. 
 
Future Directions 
Two additional studies are currently underway.  The first is a  gene set enrichment 
analysis (GSEA-SNP, see Introduction) of genes related to GPSM1 function.   GSEA-
SNP will detect if modest effect sizes in aggregate are associated with craving related 
behaviors in AD cases.  A thorough literature search was done for genes with known 
interactions with GPSM1.  Along with genes whose biological function suggests 
involvement in the GPSM1 pathway, they were compiled into the gene set shown in 
Table 2.5.   
 
 
Table 2.5. Gene set of GPSM1-related genes.  
 
 
 
ADCY1 ADRA2B DRD4 GNB2 GNG5 GRM7 HTR5A OSTM1
ADCY10 ADRA2C DRD5 GNB3 GNG7 GRM8 HTR5A PPYR1
ADCY2 ADRB1 FRMPD1 GNB4 GNG8 HRH2 HTR7 RGS4
ADCY3 ADRB2 GABBR1 GNB5 GNGT1 HRH3 INSC RIC8A
ADCY4 ADRB3 GABBR2 GNG10 GNGT2 HRH4 NPY1R
ADCY5 CCDC158 GNAI1 GNG11 GPSM1 HTR1A NPY2R
ADCY6 CHRM2 GNAI2 GNG12 GPSM2 HTR1B NPY5R
ADCY7 CHRM4 GNAI3 GNG13 GRM2 HTR1D OPRD1
ADCY8 DRD1 GNAL GNG2 GRM3 HTR1E OPRK1
ADCY9 DRD2 GNAS GNG3 GRM4 HTR1F OPRL1
ADRA2A DRD3 GNB1 GNG4 GRM6 HTR4 OPRM1
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Finally, copy number variation (CNV) is being assessed.  There are multiple 
reports of structural variation in the region.  Losses or deletions have been reported by 
six groups, a gain by one group and an insertion by another.  Figure 2.2 summarizes 
the known variation in the region.  Iafrate et al reported 1 loss in 39 control samples 
(ancestry information not provided) (Iafrate, Feuk et al. 2004) while Redon et al reported 
losses in 9 of 270 Hapmap samples, all of which had European ancestry (Redon, 
Ishikawa et al. 2006). Both studies used Comparative Genomic Hybridization (CGH).  In 
2008, Kidd et al, using a combination of sequencing, mapping and CGH, found 1 loss in 
a Hapmap sample of European descent (Kidd, Cooper et al. 2008).  Jakobsson et al 
identified 5 losses in Hapmap individuals of Siberian and Pakistani descent using 
Illumina Bead Chip calls (Jakobsson, Scholz et al. 2008).  Pang et al (Pang, MacDonald 
et al. 2010) reported a deletion in the region from the genome of Craig Venter (Levy, 
Sutton et al. 2007).  The last group to report a loss in the region, Altshuler et al, reported 
11 individuals with losses from the 1000 Genomes sequencing project (1000 Genomes 
Project Consortium 2010).  Park et al reported a gain in an Asian individual using CGH 
and subsequent sequencing (Park, Kim et al. 2010) and Teague et al reported an 
insertion in a Hapmap individual of European descent using optical mapping (Teague, 
Waterman et al. 2010). 
In summary, there are 32 reported losses or deletions and both a gain and 
insertion reported either within or proximal to GPSM1.  Further evidence is found in the 
imputed data from an unpublished GWAS in the IASPSAD sample (see Chapter Four).  
In this region on chromosome 9, the imputed genotyping probability drops to below 7% 
(ImputedFail 1 in Table 2.2), and then hovers around or below 30% for another 13kb 
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(ImputedFail 2 in Table 2.2). This could be indicative of a structural rearrangement in 
the DNA interrupting sequencing and genotyping of this region.   
Multiple studies have reported structural variation in the region of GPSM1, 
however several of the studies used the same sample (i.e. Hapmap individuals used by 
both Redon et al and Jakobsson et al) and did not find the same variants in the same 
individuals.  Therefore, it is integral within the IASPSAD and NSW TRC samples to 
validate the presence or absence of the reported variation. Three Quantitative PCR 
(qPCR)-based CNV assays have been ordered to span the reported regions of variation 
(Labeled Assay 1 – Assay 3 in Figure 2.2).  Identifying CNVs is crucial for interpreting 
association and expression analyses and will complete an initial analysis of GPSM1 in 
human AD and craving-related behavior. 
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Figure 2.2. Reported CNVs in, and proximal to, GPSM1.  Custom track visualized on 
the UCSC Genome Browser, http://genome.ucsc.edu (Kent, Sugnet et al. 2002).  
Headings on the left correspond to first author on papers reporting CNV, empirical data 
from the IASPSAD or CNV assay placement (see text).  Base pair positions are based 
on the February 2009 GRch37/hg19 assembly. 
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CHAPTER THREE 
 
Association of GRM3 and KIAA1324L with Alcohol Dependence in the Irish 
Affected Sib Pair Study of Alcohol Dependence 
 
Introduction 
Until recently, association studies for alcohol dependence (AD) have typically focused 
on genes involved in ethanol metabolism or neurotransmitter systems.  As discussed in 
the introduction, evidence of association has been observed with alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) genes as well as 
neurotransmitter candidates including the GABA receptor subunit gene GABRA2.  While 
clearly representing some progress towards the identification of loci conferring risk for 
AD, both the lack of replication and modest strength of observed association with AD 
suggest that numerous genes contributing to the risk for AD remain to be identified.   
The genome-wide association study (GWAS) has provided the opportunity to test 
for association unbiased by candidate gene selection.   At the advent of the GWAS era, 
genotyping was prohibitively expensive (Meaburn, Butcher et al. 2006).  As such, many 
of the first studies were pooled GWAS wherein genomic DNA is pooled together and 
run on a single genotyping array (Craig, Huentelman et al. 2005).  Technical artifacts 
may arise in part because it cannot be ensured that each individual is equally 
represented in the pool.  However, pooled GWAS studies can provide initial evidence of 
association signals if these can be redetected with genotyping at the individual level 
(Meaburn, Butcher et al. 2006, Kirov, Nikolov et al. 2006).  A pooled GWAS of AD in the 
Collaborative Study on the Genetics of Alcoholism (COGA) sample reported association 
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with groups of genes involved in signaling, adhesion and gene regulation (Johnson, 
Drgon et al. 2006). 
Previously, a pooled GWAS in the Irish Affected Sib Pair Study of Alcohol 
Dependence (IASPSAD) case-control sample was conducted (unpublished data), 
identifying a cluster of 8 significantly associated single nucleotide polymorphisms 
(SNPs) on human chromosome 7q21.1-q21.  The 8 SNPs map within and just upstream 
of a relatively uncharacterized locus, KIAA1324L (chr7:86,506,223-86,689,014), but are 
also in linkage disequilibrium (LD) with a metabotropic glutamate receptor and obvious 
candidate gene for AD, GRM3 (chr7:86,273,230-86,494,192).  Finally, this region lies 
within an AD linkage region from COGA (Foroud, Edenberg et al. 2000) and an alcohol 
consumption quantititative trait loci (QTL) in a syntenic region from the rat (Carr, Foroud 
et al. 1998). 
This chapter examines the cluster of LD-tagging SNPs at the individual 
genotyping level to confirm the results observed in the pooled study.  SNPs in a 660kb 
region, encompassing both KIAA1324L and GRM3, were genotyped in the IASPSAD 
case-control sample and tested for association with AD and AD symptom count.  
Replication was sought in another ascertained sample and a population sample. Finally, 
KIAA1324L and GRM3 gene expression differences were examined in human chronic 
alcoholic and control post-mortem brain tissues. 
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Methods 
Primary sample: Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) 
A detailed description of the sample is provided elsewhere (Prescott, Sullivan et 
al. 2006).  Briefly, probands were ascertained in clinical treatment facilities and hospitals 
in the Republic of Ireland and Northern Ireland between 1998 and 2002.  Probands 
were interviewed using an adapted version of the Semi-Structured Assessment of the 
Genetics of Alcoholism (SSAGA) and diagnosed with Alcohol Dependence (AD) using 
the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
criteria.   The sample is ethnically homogenous; a stipulation for inclusion in the study 
required each proband have all 4 grandparents born in Ireland, Northern Ireland, 
Scotland, Wales or England.   Controls were recruited from the National Guard and 
army reserve in the Republic of Ireland and from volunteers donating at the Northern 
Ireland Blood Transfusion Service in Northern Ireland.  Controls had no reported history 
of alcoholism.  From the original linkage sample, 562 genetically independent AD cases 
and 569 controls were selected for genotyping analyses.   
 
Replication sample: Collaborative Study on the Genetics of Alcoholism (COGA) 
Probands for the COGA sample, details of which are described elsewhere (Dick, 
Plunkett et al. 2006), were recruited throughout the United States in 6 geographic 
locations from alcohol treatment programs.  Large families were preferentially 
ascertained with a proband required to have 2 or more family members in the COGA 
sampling area and preferably sibships greater than 3.  All individuals were given the 
SSAGA interview and AD diagnosed using DSM-IV criteria. From the larger COGA 
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sample, 847 genetically independent AD cases and 552 controls of European ancestry 
were used.   
 
Replication sample: Molecular Genetics of Schizophrenia (MGS2) sample   
Details of the sample recruitment are provided elsewhere (Sanders, Duan et al. 
2008, Sanders, Levinson et al. 2010, Shi, Levinson et al. 2009).  Briefly, a survey 
research company, Knowledge Networks, Inc. (KN), used random digit dialing to recruit 
3364 adult, non-Hispanic, European American (EA) subjects from across the United 
States.  Participants were given a questionnaire (nimhgenetics.org) with a modified 
Composite International Diagnostic Interview-Short Form (CIDI-SF), screening for 
lifetime diagnoses of major psychiatric disorders such as alcohol dependence (AD).  
The final dataset after initial screening measures, laboratory quality control, and post-
GWAS quality control included 2357 European American controls (Shi, Levinson et al. 
2009) which were used as a population sample in this study.  All data (genotypes and 
phenotypes) are available by application to Database of genotypes and phenotypes 
(dbGaP, dpgap.ncbi.nlm.nih.gov, Study Accessions: phs000021.v2.p1 and 
phs000167.v1.p10 and DNA, LCLs and additional phenotypic data are available through 
the National Institute of Mental Health (NIMH) repository (nimhgenetics.org).   
 
Pooled GWAS:  
A pooled GWAS was conducted on 302 unrelated DSM-IV defined AD cases and 
264 controls from the IASPSAD sample, a subset of the larger IASPSAD case-control 
sample. Case and control pools were created in triplicate and genotyped in triplicate on 
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the Affymetrix 500K arrays by the Translational Genomics Research Institute (TGEN) 
(http://www.tgen.org/).  SNPs were ranked by silhouette scores (Lovmar, Ahlford et al. 
2005), and the top 25,000 SNPs were selected and re-ranked by t-test scores and 
finally prioritized by genomic clustering. 
 
Single Nucleotide Polymorphisms and Genotyping:  IASPSAD 
SNPs were genotyped using either multiplex or monoplex genotyping.  Multiplex 
genotyping was performed on a GenomeLab SNPstream (Beckman Coulter, Fullerton, 
CA, USA) following manufacturer's protocols, in panels of 12 SNPs matched for their 
extension type. SNP sequences were screened for repeats and homology with other 
genomic sequences prior to using the proprietary Beckman Coulter primer design 
program, Autoprimer, for constructing the multiplex panels. In instances where SNP 
sequences were repeat-rich or matching extension types were necessary for successful 
multiplex paneling, proxy SNPs with matching r2 and minor allele frequency (MAF) 
criteria were substituted.  SNPs failing in the first round of genotyping were re-paneled 
and SNPs failing twice or failing SNPstream QC parameters were dropped.  Monoplex 
reactions were performed using Taqman Assays-on-Demand (Applied Biosystems, 
Foster City, CA, USA). One SNP, rs17616282, was genotyped using a custom Taqman 
Assay (sequence available upon request).  Genotypes were called using the Analyst AD 
fluorescence detector (LJL Biosystems, Sunnyvale, CA, USA) and automated Excel 
template (van den Oord, Jiang et al. 2003).  To minimize technical variability, all 
reaction steps were performed using the Eppendorf 5075 automated liquid handler.  
Stringent evaluation of initial data is important to avoid artificial effects of genotyping 
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errors; therefore, all genotypes were independently assessed by two raters. Ambiguous 
calls were discussed and in cases of non-resolution, genotypes were dropped from the 
analyses. 
Tagging SNPs (tSNPs) were selected using CEU individuals from HapMap (data 
Rel22, NCBI B36 assembly, dbSNP b126) and TAGGER (de Bakker, Yelensky et al. 
2005) as implemented in Haploview v3.2 (Barrett, Fry et al. 2005)  using default criteria 
of MAF>0.2 and r2>0.8.  
 
Single Nucleotide Polymorphisms and Genotyping:  replication samples 
Genotypes for analysis were extracted from the COGA and MGS2 GWAS 
datasets.  As detailed elsewhere (Edenberg, Koller et al. 2010), COGA samples were 
genotyped on Illumina HumanHap1M Bead Chips (Illumina, San Diego, CA) by the 
Center for Inherited Disease Research (CIDR).  After stringent quality control measures, 
853,375 SNPs were available for analysis.  MGS2 samples were genotyped at the 
Broad Institute on Affymetrix 6.0 arrays and, after thorough filtering, 696,788 SNPs were 
available for analysis (Shi, Levinson et al. 2009).  
 
Data analysis 
IASPSAD and COGA single marker association analyses and Hardy-Weinburg 
equilibrium (HWE) testing were performed using Plinkv1.07 
(http://pngu.mgh.harvard.edu/purcell/plink) (Purcell, Neale et al. 2007).  Logistic 
regression for AD diagnosis was performed on the IASPSAD and COGA case-control 
samples, with sex as a covariate.  Linear regression with AD symptom count was 
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performed on the AD cases in the IASPSAD and COGA samples, with sex and age as 
covariates.  SNPSpD (Nyholt 2004) was used to determine the number of independent 
of tests for multiple testing corrections. 
An AD factor score phenotype was constructed in the MGS2 control sample as 
detailed by Kendler et al (Kendler, Kalsi et al. 2011). Seven questions regarding 
symptoms of AD were extracted from the CIDI-SF questionnaire. These included 
craving, dangerous use, tolerance, loss of control, great period of time spent obtaining 
alcohol or recovering from its effects, activities given up and use despite knowledge of 
harm.  Individuals who reported they never drank (n=498) were excluded from the 
analysis.  Individuals who reported the most they drank was 1-3 drinks/day were given a 
score of 0 in subsequent analyses.   All other individuals were given factor scores 
derived from the single factor solution reported in Kendler et al.  Linear regression with 
the AD symptom factor score was performed on the MGS2 control samples in 
Plinkv1.07, with sex and age as covariates. SNPSpD was used to determine the 
number of independent tests for multiple testing correction.    
Fisher’s combination test was used to test for replication (Peng, Luo et al. 2010). 
 
Gene Expression Study: postmortem tissue sample  
Superior frontal cortex (CTX), central nucleus of amygdala (CNA), and 
basolateral nucleus of amygdala (BLA) tissues from human chronic alcoholics and 
controls from the New South Wales Tissue Resource Centre (NSW TRC) located at the 
University of Sydney were used in this study.  As described in Ponomarev, 2012, DSM-
IV diagnosis of cases was based on clinical review.   A GWAS was performed on 41 
 46 
 
chronic alcoholics and 41 controls from the NSW TRC using Affymetrix 6.0 arrays (Riley 
et al, unpublished results).   Expression data was available for 17 chronic alcoholics and 
15 controls from the NSW TRC from a genomewide expression study using Illumina 
(Illumina, San Diego, CA) HumanHT-12 whole genome expression bead chips 
(Ponomarev, Wang et al. 2012).  The samples from these studies were not congruent, 
so the overlap between the datasets, 12 chronic alcoholics and 8 controls, was chosen 
for analyses. 
 
Gene expression study: statistical methods 
Sex, age, PMI (post-mortem interval), liver pathology, neuropathology, 
toxicology, brain pH, and smoking demographics were provided by the NSW TRC.  As 1 
out of the 20 samples was female, sex was not included as a covariate.  RNA integrity 
number (RIN) values were provided for each tissue, however a Fisher’s exact test was 
non-significant for differences between cases and controls in the CTX, CNA, and BLA 
(p=0.586, 1, and 0.906, respectively).  RIN was therefore not included as a covariate.  
Liver pathology, neuropathology, and toxicology were re-coded numerically for 
subsequent analyses.  Principal components analysis (PCA) was run in SASv9.3 using 
age, PMI, liver pathology, neuropathology, toxicology, brain pH, and smoking.  The first 
5 components explained 90% of the variance in the dataset (see Chapter Two, Figure 
2.1).  Component scores for the first 5 components were used as covariates in the 
analyses.   
Four genes lying within the tagging region in the IASPSAD sample were chosen 
for inclusion in the study: GRM3 (Illumina identifiers ILMN_1679532 and 
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ILMN_2078975), KIAA1324L (Illumina identifier ILMN_1652371), DMTF1 (Illumina 
identifiers (ILMN_1750075 and ILMN_2119486), and c7orf23 (Illumina identifier 
ILMN_1751143).  Differences in gene expression between cases and controls were 
analyzed using the PROC GLM – MANOVA test in SASv9.3 and raw p-values corrected 
for the 6 probes tested.  Probes with p-values surviving multiple testing correction were 
analyzed using ANOVA in each brain region using the PROC GLM test in SASv9.3. 
Linear regression tests for allele specific expression differences were performed in Plink 
v1.07 with the aforementioned component scores used as covariates.   
 
Results 
As described previously, the pooled GWAS of AD in the IASPSAD case-control sample 
identified a cluster of 8 significantly associated SNPs on human chromosome 7q21.1-
q21.12 (unpublished data).   This region was previously implicated in a COGA AD 
linkage scan (Foroud, 2000) and in a rat alcohol consumption QTL (Carr, Foroud et al. 
1998).  Since pooled GWAS datasets are susceptible to technical artifacts, the 8 SNPs 
were individually genotyped in the IASPSAD sample subset sent for pooled genotyping. 
The results were comparable between the pooled GWAS and individual genotyping 
(Table 3.1).  All 8 SNPs remained nominally associated with AD.   
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Table 3.1. Validation of pooled GWAS results by individual genotyping in the 
IASPSAD.   
 
All 8 SNPs remained nominally significant (p≤0.05) after individual genotyping in a 
subset of the IASPSAD sample.  SNPs rs1635037-rs2373338 fall within a single LD 
block and are redundant. 
 
 
 
The SNP cluster identified in the pooled GWAS lies within and upstream of 
KIAA1324L, and is in LD with a metabotropic glutamate receptor, GRM3.   Therefore, a 
~660kb region (chr7: 86039131-866992499) surrounding the initial cluster of associated 
SNPs, and encompassing a large block of LD, was analyzed for tagging SNPs (tSNPs). 
Thirty-two tSNPs were identified, 2 of which were already genotyped in the validation of 
the pooled results.  Two SNPs were unavailable for both multiplex and monoplex 
genotyping.  Five SNPs genotyped poorly and were dropped.  Two SNPs showed 
deviation from HWE (p < 0.001) in control samples and were excluded.  When 
combined with the 2 previously genotyped tSNPs, a total of 23 out of 30 available 
tSNPs (77%) genotyped successfully.  Four additional SNPs were chosen for 
genotyping in the IASPSAD for consistency with the higher density GWAS data from the 
COGA and MGS replication samples, one of which genotyped poorly and was dropped.  
Pooled GWAS Individual Genotyping
SNP Cs freq Cn Freq Cs freq Cn Freq p-value
rs1635037 0.875 0.758 0.720 0.664 0.0055
rs1767741 0.744 0.620 0.720 0.666 0.0073
rs1767735 0.840 0.723 0.719 0.664 0.0065
rs767435 0.818 0.662 0.720 0.670 0.0135
rs767434 0.733 0.526 0.722 0.666 0.0059
rs1635010 0.899 0.779 0.722 0.668 0.0078
rs2373338 0.780 0.607 0.719 0.666 0.0086
rs1859122 0.761 0.624 0.780 0.723 0.0023
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Of the 26 successfully genotyped SNPs in the IASPSAD sample (23 tSNPs plus 3 
additional SNPs), 1 SNP was removed for excessive missingness (0.13).  Ninety-eight 
samples were removed for having ≥ 8 missing genotypes (≥32%).  After data cleaning, 
a total of 25 tSNPs were analyzed for tests of association on 537 cases and 496 
controls.   
Table 3.2 shows the IASPSAD case-control sample association results for AD.   
A number of SNPs in the region were nominally associated with AD.  SNPSpD (Nyholt 
2004) was used to ascertain the number of independent SNPs for multiple testing 
correction.  After correcting for 15 SNPs, rs802467 and rs1859122 remained 
significantly associated with AD (p<0.0034) and rs1635037 was borderline significant. 
Rs802467 and rs1635037 are located in introns of GRM3 and KIAA1324L, respectively.   
Rs802467 is in LD with SNPs in GRM3, only, and similarly rs1635037 is only in LD with 
SNPs in KIAA1324L.  Rs1859122 maps ~44.5 kb upstream of KIAA1324L and is in 
weak LD (r2<0.3) with SNPs in both KIAA1324L and GRM3.  
Based on the association results in our sample, replication was attempted in an 
independent sample.  Table 3.2 summarizes the association results for AD in the COGA 
sample.   There was no evidence of association in COGA with SNPs previously 
implicated in the IASPSAD sample. However, one SNP within KIAA1324L and one SNP 
in DMTF1, distal to KIAA1324L, were nominally associated with AD in COGA.  The 
most significant SNP, rs17609037, is only in LD with SNPs within KIAA1324L. SNPSpD 
identified 15 independent SNPs and after multiple testing correction, no SNPs remained 
significant (p<0.0034).  Analysis of AD symptom count in the IASPSAD and COGA 
samples provided little additional association evidence (Table 3.3).  Association results  
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Table 3.2. Case-control association results for AD in the IASPSAD and COGA.  
Nominal p-values shown. An odds ratio (OR) > 1 indicates the minor allele (second in 
the "alleles" column) increases the odds of having AD. If the identical SNP genotyped in 
the IASPSAD sample was not available, proxy SNPs were analyzed (if available) and 
are noted in italics along with r2 values. *SNP was significant after multiple testing 
correction. 
 
 
IASPSAD COGA
Gene SNP Alleles Position OR p-value proxy SNP r 2 Alleles OR p-value
rs12668991 T/C 86065377 0.946 0.5629 rs12704277 1.00 T/C 0.975 0.7872
rs274621 A/G 86110735 1.000 0.9996 rs274621 -- A/G 1.132 0.1809
GRM3 rs1581638 A/G 86146536 1.341 0.0465 rs1830249 1.00 T/C 1.099 0.5154
GRM3 rs802467 T/C 86166546 1.318 0.0032* rs802467 -- T/C 0.961 0.6428
GRM3 rs1405875 T/C 86168009 1.136 0.1892 rs274627 0.95 G/T 0.929 0.3905
GRM3 rs2299218 C/T 86173748 0.737 0.0079 rs2299218 -- C/T 0.944 0.5801
GRM3 rs10239714 T/C 86189153 1.126 0.2325 rs2189813 1.00 T/C 0.948 0.5766
GRM3 rs6943659 T/C 86233862 1.051 0.6021 rs6943659 -- T/C 1.039 0.6801
GRM3 rs6961677 C/T 86241147 1.086 0.4012 rs2282965 1.00 T/C 0.923 0.3902
GRM3 rs10277739 C/T 86258176 1.037 0.7211 rs2237562 1.00 T/C 0.900 0.2594
GRM3 rs10234440 T/C 86258313 1.013 0.9135 rs1468413 0.95 C/A 0.867 0.1979
GRM3 rs7788115 A/T 86310267 0.924 0.5294 rs7797095 0.94 C/T 0.882 0.2653
GRM3 rs7781414 A/G 86321515 0.929 0.4640 rs7781178 1.00 A/G 0.930 0.4433
KIAA1324L rs2788868 A/T 86406457 0.857 0.0997 rs1767721 1.00 A/C 0.942 0.5115
KIAA1324L rs17609037 T/C 86444443 1.245 0.4665 rs17609037 -- T/C 1.983 0.0074
KIAA1324L rs1635037 C/T 86458946 0.758 0.0037 rs1024376 1.00 G/A 1.007 0.9374
KIAA1324L rs13238095 G/A 86481991 0.763 0.0172 rs9886155 1.00 T/G 1.028 0.7956
rs4728666 G/A 86516142 0.872 0.1361 rs4728666 -- G/A 1.100 0.2983
rs11768112 T/C 86518964 0.830 0.0351 rs4728674 1.00 G/A 1.067 0.4637
rs2189519 C/T 86524116 0.754 0.0091 rs12704340 1.00 C/T 0.975 0.8000
rs11970980 A/C 86548288 0.767 0.0043 rs11970980 -- A/C 0.966 0.6968
rs1859122 C/T 86571409 0.719 0.0012*
rs9886113 C/A 86575011 1.154 0.1514 rs9886113 -- C/A 0.998 0.9863
DMTF1 rs17616282 G/A 86629940 1.103 0.7131 rs17616282 -- G/A 0.626 0.0339
c7orf23 rs17766292 A/G 86668126 0.864 0.1078 rs17766292 -- A/G 0.968 0.7155
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Table 3.3. Association results for AD symptom count in the IASPSAD, COGA and 
MGS2 samples.   
Nominal p-values shown. A positive regression coefficient (Beta) indicates the minor 
allele (second in the "alleles" column) increases the phenotype. If the identical SNP 
genotyped in the IASPSAD sample was not available, proxy SNPs were analyzed (if 
available) and are noted in italics along with r2 values. 
 
 
 
IASPSAD COGA MGS2 
Gene SNP Alleles Position Beta p-value proxy SNP r 2 Alleles Beta p-value proxy SNP r 2 Alleles Beta p-value
rs12668991 T/C 86065377 -0.159 0.0099 rs12704277 1.00 T/C -0.009 0.4890 rs12668991 -- T/C 0.027 0.2077
rs274621 A/G 86110735 0.056 0.3548 rs274621 -- A/G 0.002 0.8477 rs274621 -- A/G -0.007 0.7430
GRM3 rs1581638 A/G 86146536 -0.130 0.1340 rs1830249 1.00 T/C -0.009 0.6200 rs1507589 1.00 T/G 0.075 0.0300
GRM3 rs802467 T/C 86166546 -0.037 0.5246 rs802467 -- T/C 0.006 0.6192 rs802467 -- T/C -0.006 0.7842
GRM3 rs1405875 T/C 86168009 0.055 0.3700 rs274627 0.95 G/T 0.011 0.3640 rs187993 0.95 T/G -0.009 0.6583
GRM3 rs2299218 C/T 86173748 -0.094 0.2190 rs2299218 -- C/T -0.022 0.1317 rs802458 0.82 G/C -0.003 0.8889
GRM3 rs10239714 T/C 86189153 -0.079 0.1998 rs2189813 1.00 T/C -0.019 0.1455 rs10239714 -- T/C 0.023 0.3150
GRM3 rs6943659 T/C 86233862 -0.108 0.0723 rs6943659 -- T/C -0.018 0.1611
GRM3 rs6961677 C/T 86241147 -0.102 0.0968 rs2282965 1.00 T/C -0.018 0.1702 rs2282965 1.00 T/C 0.027 0.2229
GRM3 rs10277739 C/T 86258176 -0.115 0.0717 rs2237562 1.00 T/C -0.007 0.6062 rs7804907 1.00 C/T 0.031 0.1657
GRM3 rs10234440 T/C 86258313 -0.079 0.2810 rs1468413 0.95 C/A -0.013 0.3979
GRM3 rs7788115 A/T 86310267 -0.034 0.6723 rs7797095 0.94 C/T -0.009 0.5803 rs7788115 -- A/T -0.002 0.9537
GRM3 rs7781414 A/G 86321515 -0.053 0.4126 rs7781178 1.00 A/G -0.008 0.5547 rs7781178 1.00 A/G 0.024 0.2819
KIAA1324L rs2788868 A/T 86406457 -0.043 0.4834 rs1767721 1.00 A/C -0.003 0.7995 rs2788868 -- A/T 0.014 0.5175
KIAA1324L rs17609037 T/C 86444443 0.293 0.1111 rs17609037 -- T/C 0.030 0.3248
KIAA1324L rs1635037 C/T 86458946 -0.070 0.2765 rs1024376 1.00 G/A -0.011 0.3503 rs1635037 -- C/T 0.018 0.4027
KIAA1324L rs4728658 A/G 86465255 rs4728658 -- A/G 0.197 0.0170
KIAA1324L rs13238095 G/A 86481991 -0.022 0.7665 rs9886155 1.00 T/G 0.004 0.7939 rs10282295 1.00 C/G 0.011 0.6562
rs4728666 G/A 86516142 0.044 0.4616 rs4728666 -- G/A -0.002 0.8677 rs4728666 -- G/A -0.026 0.2315
rs11768112 T/C 86518964 0.086 0.1304 rs4728674 1.00 G/A -0.001 0.9574 rs11768112 -- T/C -0.019 0.3545
rs2189519 C/T 86524116 0.085 0.2252 rs12704340 1.00 C/T -0.015 0.2063 rs12704339 1.00 G/A 0.028 0.2457
rs11970980 A/C 86548288 0.035 0.5787 rs11970980 -- A/C -0.009 0.5343
rs1859122 C/T 86571409 -0.019 0.7925 rs1859122 -- C/T -0.002 0.9161
rs9886113 C/A 86575011 -0.020 0.7592 rs9886113 -- C/A -0.002 0.8842 rs9886113 -- C/A -0.011 0.6356
DMTF1 rs17616282 G/A 86629940 0.027 0.8732 rs17616282 -- G/A 0.054 0.1311
c7orf23 rs17766292 A/G 86668126 0.016 0.7891 rs17766292 -- A/G -0.009 0.4532 rs17766292 -- A/G 0.001 0.9449
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for an AD symptom factor score phenotype (see Methods) from a third independent 
sample, the MGS2 controls, are listed in the Table 3.3.  There was no SNP-to-SNP 
replication between any of the samples.  Two SNPs within GRM3 and one SNP within 
KIAA1324L were nominally associated in the MGS2 controls. The most significantly 
associated SNP, rs1999945, lies within KIAA1324L but is in moderate LD with SNPs 
within GRM3 (r2~0.64).  After correcting for 13 independent SNPs, no SNPs remained 
significantly associated (p<0.0039).  Fisher’s combination test was used to test for 
replication in the COGA and MGS2 datasets.  The p-value of 0.115 (chi-square 7.46, 
df=4) was suggestive for replication, though not significant.   
In an effort to clarify the primary risk locus in the associated region, expression of 
four genes in human postmortem brain tissues from the New South Wales Tissue 
Resource Center was examined. Expression was analyzed between chronic alcoholics 
(n=12) and controls (n=8) in three brain regions with implications for reward processing: 
the basolateral nucleus of amygdala (BLA), central nucleus of amygdala (CNA), and 
superior frontal cortex (CTX).  Multivariate analysis of variance (MANOVA) results 
showed no expression differences for KIAA1324L, DMTF1 and c7orf23 (Table 3.4A).  
One probe for GRM3 showed significant expression differences between cases and 
controls after multiple testing correction.  Separate analysis of variance (ANOVA) within 
each brain region showed significantly higher GRM3 expression in controls compared to 
cases (Table 3.4B and Figure 3.1).  No allele-specific expression differences for SNPs 
surviving multiple testing correction were found for any of the four genes in the 
associated LD block (Table 3.5). 
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Table 3.4.  Gene expression differences between chronic alcoholics and controls.   
 
(A). MANOVA results for 4 genes of interest.  Significant MANOVA p-values were 
corrected for the six tested probes.  (B). GRM3 (ILMN_2078975) expression was 
analyzed in the basolateral nucleus of amygdala (BLA), central nucleus of amygdala 
(CNA), and superior frontal cortex (CTX).  Raw ANOVA p-values are shown.   
 
 
 
 
 
 
Table 3.5 Association results for allele-specific expression differences.   
Association results for allele-specific expression differences in the NSW TRC samples. 
 Bonferroni corrected p-values shown for each probe with 3 SNPs in 3 tested brain 
regions: the basolateral nucleus of amygdala (BLA), central nucleus of amygdala 
(CNA), and superior frontal cortex (CTX). P-values were corrected, within brain region, 
for 18 tests (3 SNPs x 6 probes). SNPs were chosen for analysis based on significant 
association results in the IASPSAD case-control sample. Rs802467 and rs1859122 
were significantly associated with AD after multiple testing correction and rs1635037 
wasborderline significant. 
 
A. Gene Illumina Identifier p-value (corrected) B. Tissue P-value
GRM3 ILMN_1679532 0.2154 BLA 0.002
GRM3 ILMN_2078975 0.0027 (0.019) CNA 0.031
KIAA1324L ILMN_1652371 0.3419 CTX 0.003
DMTF1 ILMN_1750075 0.0430 (0.301)
DMTF1 ILMN_2119486 0.3761
c7orf23 ILMN_1751143 0.1957
BLA CNA CTX
Gene (Illumina probe) rs802467 rs1635037 rs1859122 rs802467 rs1635037 rs1859122 rs802467 rs1635037 rs1859122
GRM3 (ILMN_1679532) >1 >1 >1 >1 >1 >1 >1 0.8896 >1
GRM3  (ILMN_2078975) >1 >1 >1 >1 >1 >1 >1 >1 >1
KIAA1324L (ILMN_1652371) >1 >1 >1 >1 >1 >1 >1 >1 >1
DMTF1  (ILMN_1750075) >1 >1 >1 >1 >1 >1 0.5840 >1 >1
DMTF1  (ILMN_2119486) >1 >1 >1 >1 >1 >1 0.1620 >1 >1
c7orf23 (ILMN_1751143) >1 >1 >1 >1 >1 >1 >1 >1 >1
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A. B.                                                                                                                      
C.    
Figure 3.1. Significant GRM3 gene expression differences in human chronic 
alcoholic and control brain tissues. Box plots show expression differences in controls 
(1) and cases (2) in three brain regions: basolateral nucleus of amygdala (A), central 
nucleus of amygdala (B), and superior frontal cortex (C). 
 
 
 
 55 
 
Discussion 
On 7q21.1-q21.12, a region previously implicated in AD in humans and ethanol 
consumption in rats, three independent samples were analyzed for association with 
AD/AD symptom count.  In the clinically ascertained IASPSAD sample, 2 SNPs were 
associated with AD after multiple testing correction. The minor allele of rs802467, 
intronic to GRM3 and only in LD with GRM3 SNPs, was associated with increased risk 
for AD.  Replication was suggestive, though not significant, in another ascertained 
sample, COGA, and a population sample, the MGS2 controls.  However, within the 
COGA dataset, the most significant SNP (rs17609037) was located in an intron of 
KIAA1324L, and only in LD with SNPs in that locus.  Similarly, in the MGS2 controls, the 
most significant SNP (rs1999945) was located within an intron of KIAA1324L but was in 
moderate LD with SNPs in GRM3 as well.  While positive association results in multiple 
samples support the existence of a gene or genes influencing AD risk within this 
genomic region, the lack of direct replication remains a limitation.  Associated SNPs in 
one sample show no association in any other sample. This could be influenced by 
subtle differences in patterns of LD between the samples (Figures 3.2-3.4).   
 
 56 
 
Figure 3.2.  LD in the associated region of chromosome 7 in IASPSAD controls.    
Haploview shading based on r2 values. 
 
 
 
Figure 3.3.  LD in the associated region of chromosome 7 in COGA controls of 
European descent.  Haploview shading based on r2 values.     
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Figure 3.4.  LD in the associated region of chromosome 7 in MGS2 controls of 
European descent.  Haploview shading based on r2 values.     
 
 
 
 
 
To further investigate which gene in the region may contribute to risk for AD, the 
expression of the four genes in the associated LD block in chronic human alcoholic and 
control postmortem brain samples from the New South Wales Tissue Resource Centre 
was analyzed.  A probe tagging the 3’UTR of GRM3 showed significant gene 
expression differences between cases and controls in the BLA, CNA and CTX.  
Expression was significantly higher in the control samples compared to the chronic 
alcoholic samples.  No other genes in the region showed significant expression 
differences, though the small sample size (n=12 cases and n=8 controls) may have 
limited power to detect more subtle differences.   
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GRM3 encodes a Group II metabotropic glutamate receptor (mGlu3); a G-protein 
coupled receptor that functions to inhibit adenylate cyclase and decrease levels of cyclic 
adenosine monophosphate (cAMP) (Lyon, Kew et al. 2008).  Group II receptors (mGlu2 
and mGlu3) also negatively regulate glutamate release (Gass, Olive 2008).  Agonists of 
the Group II receptors result in lower levels of glutamate in the synapse (Cannady, 
Grondin et al. 2011).   A GWAS on comorbid alcohol and nicotine dependent Australian 
and Dutch samples yielded one SNP within GRM3, rs218916, in the top 30 most 
significant SNPs (Lind, Macgregor et al. 2010).  Although there has been substantial 
research on GRM3 in other psychiatric and related phenotypes, there is little additional 
evidence specifically linking GRM3 to AD or alcohol-related phenotypes in humans.   
However, a recent study by Xia and colleagues implicated GRM3 in functional 
abnormalities seen in the prefrontal cortex of AD individuals (Xia, Ma et al. 2012). 
Model organism research in rodents has yielded additional insight on the 
relationship between GRM3 expression and alcohol related phenotypes.  Grm3 
knockout mice showed no differences in response to ethanol (Corti, Andreoli et al. 
2004), however Grm3 is significantly ethanol responsive in the prefrontal cortex of 
mouse BXD Recombinant Inbred lines and is a hub in ethanol-responsive gene network 
analyses (Wolen, Phillips et al. 2012).  This suggests that Grm3 expression changes in 
response to ethanol exposure and may have a central role in ethanol responsive 
pathways in mice.  In rats, activation of Group II receptors results in decreased ethanol 
seeking (Rodd, McKinzie et al. 2006), stress-induced (Sidhpura, Weiss et al. 2010)   
and cue-induced (Zhao, Dayas et al. 2006) relapse behavior and drinking (Sidhpura, 
 59 
 
Weiss et al. 2010, Backstrom, Hyytia 2005).  Taken together, results from rodents 
implicate Grm3 in ethanol response and ethanol-related behaviors. 
However, the association seen with KIAA1324L, and whether or not it represents 
an independent signal, cannot be excluded.  The KIAA1324L gene encodes a one-pass 
transmembrane protein that is evolutionarily conserved and widely expressed (Araki, 
Kusakabe et al. 2011).  The Xenopus laevis ortholog of KIAA1324L, xEIG121L, has 
been implicated in bone morphogenetic protein (BMP) signaling (Araki, Kusakabe et al. 
2011) and additional studies suggest alcohol decreases BMP-mediated Smad signaling 
in the liver of chronically exposed mice (Gerjevic, Liu et al. 2012).  Though tenuous, the 
literature suggests that KIAA1324L may have a role in ethanol-related signaling. 
This chapter investigated a region on human chromosome 7 associated with AD 
in the IASPSAD sample.  Of the four genes located in the region, association and 
expression studies most strongly implicate GRM3.  Evidence from the model organism 
literature implicates activation of Group II metabotropic glutamate receptors in 
“protective” alcohol-related behaviors and Grm3, specifically, in ethanol responsiveness. 
Though the signal is somewhat diffuse, KIAA1324L cannot be excluded as a potential 
risk locus for AD.  KIAA1324L’s relationship with alcohol-related behaviors is not well 
documented, but is known to be involved in BMP signaling, which in turn may be altered 
due to alcohol exposure.  Collectively, prior evidence and results from this chapter 
suggest that further research is warranted to investigate variation in and expression of 
GRM3 in human AD and related phenotypes. 
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Future Directions 
Two final projects will be completed in an effort to clarify whether GRM3, KIAA1324L or 
both loci are risk factors for AD.   First, an expression quantitative trait loci (eQTL) study 
is currently underway in the aforementioned NSW TRC samples using expression data 
from Ponomarev et al and GWAS data from Riley et al (see Methods).  Initial results 
show significant evidence for two cis-eQTLs in GRM3.  Secondly, the recently released 
data from the Encyclopedia of DNA Elements (ENCODE) Consortium  (ENCODE 
Project Consortium, Dunham et al. 2012) will be interrogated to see if any if the 
associated SNPs reported in this chapter are located in regulatory regions for GRM3 or 
KIAA1324L.  Preliminary review suggests that rs1859122 (significant after multiple 
testing correction in the IASPSAD sample) is less than 150bp away from an enhancer of 
KIAA1324L (Figure 3.5).  Completion of these two projects will strengthen the large 
body of evidence presented in this chapter linking this region of chromosome 7 to AD. 
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Figure 3.5. ENCODE graphic for the associated region on chromosome 7.  All 9 
SNPs nominally associated with AD in the IASPSAD study are represented as crosses.  
Rs1859122  (located on the far right of the graphic) is 5’ to KIAA1324L and is located 
near an enhancer of that locus.  (Figure courtesy of Dr. Aaron Wolen.) 
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CHAPTER FOUR 
 
A Genome-wide Association Study of Initial Sensitivity in the Irish Affected Sib 
Pair Study of Alcohol Dependence 
 
 
Introduction 
As discussed previously, alcohol dependence (AD) is a dichotomous clinical diagnosis. 
Researchers have had modest success finding genes associated with AD, but analyzing 
alcohol-related phenotypes (ARPs) is an attractive alternative.  ARPs are specific 
factors though to contribute to the overall risk for AD.  While AD is likely due in part to 
the action of numerous genes, ARPs, like physiological measurements, may be closer 
to the underlying genetic risk factors, may be localized to specific regions of the genome 
and are more likely to comprise smaller gene networks.  Such a reduction in genetic 
complexity results in increased statistical power for the proposed association studies.  
Additionally, associated genes can be analyzed in the light of a relatively simpler 
biological component of a much more complex clinical phenotype.   
Level of response to alcohol (LR) is a powerful indicator of future alcohol use 
problems, alcohol use disorders and alcohol consumption.  Individuals with low LR feel 
less effect from each drink and are at an increased risk for alcohol use problems, 
typically drinking more heavily than individuals with high LR (Schuckit, Smith et al. 2012, 
Schuckit, Smith et al. 2007, Schuckit, Smith et al. 2011, Schuckit, Smith et al. 2009, 
Schuckit, Smith 2001, Trim, Schuckit et al. 2009, Daeppen, Landry et al. 2000, 
Schuckit, Smith et al. 2009, Schuckit, Smith et al. 2008).  This correlation has been 
documented across sexes (e.g., men (Schuckit, Smith et al. 2004) and women 
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(Schuckit, Smith et al. 2003) ), ages (e.g, adolescents (Schuckit, Smith et al. 2005)), 
and races (e.g., African Americans (Pedersen, McCarthy 2009) ).  
A direct alcohol challenge can be given to experimental subjects to measure their 
level of response to alcohol.  However, this test is expensive and time consuming.  
Schuckit et al developed a (SRE) instrument that provides information on the same 
physiological measurements, but is a paper survey and takes less than five minutes to 
complete (Schuckit, Tipp et al. 1997, Schuckit, Smith et al. 1997).  When the SRE was 
given to ninety-eight men who also completed the alcohol challenge test, the correlation 
between the results was 0.82 (p<0.001) (Schuckit, Tipp et al. 1997).  The SRE asks 
“how many drinks did it take for you to begin to feel different, feel a bit dizzy or begin to 
slur your speech, begin stumbling or walking in an uncoordinated manner, or pass out 
or fall asleep when you did not want to?” during the first five times the subject drank.   
An initial sensitivity (ISENS) score is computed based on the number of drinks reported 
divided by the number of effects endorsed. 
LR is heritable with estimates from twin studies ranging from 40-60% (Heath, 
Madden et al. 1999, Viken, Rose et al. 2003, Martin, Oakeshott et al. 1985).  Among 
first degree relatives, the LR correlation is reported to be between 0.14 and 0.22 
(Schuckit, Smith et al. 2005).  Furthermore, children of alcoholics, when compared to 
other family members, have lower LR (de Wit, McCracken 1990, Eng, Schuckit et al. 
2005).  Given the heritability of the trait and the predictive ability of low LR for future 
alcohol use problems, there has been substantial interest in identifying its genetic risk 
factors. 
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Multiple linkage studies have examined LR.  In a population of American Indians, 
strong linkage was seen on chromosomes 6 and 9 (Ehlers, Gizer et al. 2010).  The 
Collaborative Study on the Genetics of Alcoholism (COGA) found linkage with 
KCNMA1, HTR7 and SLC18A2 (Schuckit, Wilhelmsen et al. 2005) and on 
chromosomes 11,13, 20 and 21 (Schuckit, Edenberg et al. 2001).  In a U.S. sample 
from San Diego, linkage was found on chromosomes 10, 11 and 22 (Wilhelmsen, 
Schuckit et al. 2003) and with the CYP2E1 locus (Webb, Lind et al. 2011).  In the Irish 
Affected Sib Pair Study of Alcohol Dependence (IASPSAD), linkage peaks were 
identified on chromosomes 1 and 11 (Kuo, Neale et al. 2006). 
The IASPSAD ISENS linkage peak on chromosome 1 is particularly intriguing.  
The ISENS peak at D1S2726 (LOD=1.89, p-value=0.002) is paired with a proximal 
alcohol tolerance peak at D1S219 (LOD 1.78, p-value=0.002) (Kuo, Neale et al. 2006).  
The 41Mb region between the peaks (chr1: 69,841,001-111,184,618) has been 
implicated in three other independent, alcohol-related linkage studies.  The first sample, 
comprised of 18 UK families, showed linkage to 1p22.1-11.2 (peak at D1S1588, LOD 
1.8) using the Research Diagnostic Criteria for Alcoholism (RDCA) as the phenotype 
(Guerrini, Cook et al. 2005).  Second, 87 trios (proband and parents) obtained in 
Connecticut peaked at D1S406 (P=0.005) using a TDT test with AD as the phenotype 
(Lappalainen, Kranzler et al. 2004).  Third, COGA has repeatedly found evidence for 
linkage to chromosome 1, a brief summary of which is presented below. 
Data from the initial COGA sample gave evidence of linkage for AD to D1S532 
and D1S1588 (P=0.0003) (peaks at D1S1588, LOD 2.93 and D1S224, LOD 1.65) 
(Reich, Edenberg et al. 1998).  After genotyping an additional 105 families, and 
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obtaining a replication sample of 157 families, the COGA data was reanalyzed.  The 
new linkage peaks for AD were located at D1S1588 (LOD 2.5) and D1S224/D1S1665 
(LOD 1.7) (Foroud, Edenberg et al. 2000).  The aforementioned replication sample 
peaked at D1S224 (LOD 1.6) using ICD-10 AD criteria.  When both samples were 
analyzed together (original COGA data with 105 new families and the replication 
sample), there was a linkage peak at D1S2614/D151588 (LOD 2.6).  The COGA data 
was further analyzed with alternative phenotypes for AD.  SRE scores for ISENS in 745 
sib pairs showed a linkage peak at D1S224 (LOD 1.9) (Schuckit, Wilhelmsen et al. 
2005, Schuckit, Edenberg et al. 2001).   AD and major depression (MD) analyzed 
together peaked at D1S1648/S1S1588 (LOD 5.12) while an “AD or MD” phenotype 
peaked at D1S224 (LOD 4.66) (Nurnberger, Foroud et al. 2001).  Lastly, when the data 
were analyzed with a sex-and age-adjusted multiple threshold liability (MTL) model, two 
peaks were found: D1S532 (LOD 5.17) and D1S1665 (LOD 2.61).  The MTL model 
included persons with AD and controls and used the differential severity of different 
diagnostic scales (Corbett, Saccone et al. 2005).  In summary, four separate samples, 
encompassing thirteen different analyses, have found significant evidence of linkage to 
the same region on chromosome 1 for AD or ARPs.  These results suggest the 
presence of a significant region for ISENS and ARPs surrounding the IASPSAD linkage 
peak on chromosome 1. 
Human candidate gene studies have found association between LR and 
GABRG1 (Ray, Hutchison 2009) , GABRA6 (Schuckit, Mazzanti et al. 1999), GAD1 
(Kuo, Kalsi et al. 2009), SLC6A4 (Hinckers, Laucht et al. 2006) and the long allele of 
HTTLPR (Hu, Oroszi et al. 2005).  Rs1051730 on chromosome 15 has been implicated 
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in LR.  It is located in a dense block of linkage disequilibrium (LD) but obvious candidate 
genes in the region are CHRNA5, CHRNA3 and CHRNB4 (Joslyn, Brush et al. 2008).  
A recent genome-wide analysis found overrepresentation of neuronal signaling genes 
associated with LR (Joslyn, Ravindranathan et al. 2010).                        . 
ISENS is a heritable, alcohol-related phenotype consistently correlated with risk 
for AD.  Understanding the genetic risk factors for initial sensitivity to alcohol would be a 
powerful therapeutic tool.  This chapter presents initial data from a genome-wide 
association study (GWAS) on ISENS in the IASPSAD sample.  Single nucleotide 
polymorphism (SNP) association analysis and gene-based association analysis are 
used to identify loci associated with risk for the phenotype.   
 
Methods 
Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD): 
A detailed description of the sample is provided elsewhere (Prescott, Sullivan et 
al. 2006).  Briefly, probands were ascertained in clinical treatment facilities and hospitals 
in the Republic of Ireland and Northern Ireland between 1998 and 2002.  Probands 
were interviewed using an adapted version of the Semi-Structured Assessment of the 
Genetics of Alcoholism (SSAGA) and diagnosed with Alcohol Dependence (AD) using 
criteria from the fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV).   The sample is ethnically homogenous; a stipulation for inclusion 
in the study required each proband have all 4 grandparents born in Ireland, Northern 
Ireland, Scotland, Wales or England.  
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Initial Sensitivity Phenotype 
Initial Sensitivity (ISENS) was measured with the Self-Rating for the Effects of 
Alcohol (SRE) instrument developed by Schuckit et al (Schuckit, Tipp et al. 1997).  
ISENS is defined as the number of drinks needed for a person to feel the effects of 
ethanol during their first five times he or she drinks.   The SRE queries four different 
effects and asks “how many drinks did it take for you to begin to feel different, feel a bit 
dizzy or begin to slur your speech, begin stumbling or walking in an uncoordinated 
manner, or pass out or fall asleep when you did not want to?”  The phenotypic score for 
each individual was calculated as the number of total drinks reported divided by the total 
number of symptoms endorsed. 
 
GWAS: pre-genotyping QC of IASPSAD cases 
DNA from all probands and affected siblings from the IASPSAD was quantified 
using both spectrophotometry and Quant-iT Picogreen (Life Technologies, Carlsbad, 
CA) technology.   200ng of each DNA sample was run on a 2% agarose gel to assess 
degradation.  Finally, all samples were sex-typed with sex chromosome-specific  
quantitative PCR (qPCR) using the Quantifiler Duo DNA Quantification Kit (Life 
Technologies, Carlsbad, CA).  Only high molecular weight samples (bands > 800bp) 
with DNA concentrations ≥ 50ng/ul and with genotypic sex matching phenotypic sex 
were sent for genotyping.  
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Genotyping, QC and Calling Algorithms 
815 samples from the IASPSAD, including eleven sets of parents to assess 
Mendelian errors, were sent to Vanderbilt University for genotyping on Affymetrix v6.0 
arrays (Santa Clara, CA).  2000 Biobank controls from the Irish Blood Transfusion 
Service were also genotyped on Affymetrix v6.0 arrays at either the Affymetrix or Broad 
Institute core facilities.   Arrays were called used the Affymetrix Birdseed v2 algorithm.  
Thirty-five samples were removed post-genotyping for CQC values <0.4, Nsp/Sty CQC 
values < 0 or discrepant genotypic sex calls.  Arrays were then re-called using 
BEAGLECALL software (Browning, Yu 2009)  in an effort to minimize site differences in 
genotyping.  BEAGLECALL is an iterative process which starts with the fluorescent 
intensity calls and then incorporates haplotypic information from the sample with 
increasingly stringent calling filters. Subsequently, samples and SNPs underwent a 
thorough QC process.  Samples were removed if the phenotypic and genotypic sex 
were discordant, they had excessive Mendelian errors, they were ancestry, 
heterozygosity or mean pi-hat outliers, their call rates were ≤ 98%, or if there was a 
DNA mix-up.  SNPs were removed if Hardy-Weinburg equilibrium (HWE) p-values < 
1x10-6, the minor allele frequency (MAF) < 1%, there were Mendelian errors, they were 
duplicates, their call rate < 98% or if there was differential missingness between cases 
and controls. After QC, 676,736 SNPs were available for 710 probands and affected 
siblings and 1755 controls. 
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Imputation 
Genotypes were imputed using IMPUTE2 (Howie, Donnelly et al. 2009)                                                                                                          
with the March 2012 1000 Genomes reference haplotype panel (1000 Genomes Project 
Consortium 2010).   Probabilities were converted to dosages (based on number of 
minor alleles) using MACH2 (Scott, Mohlke et al. 2007).  Post-imputation filtering 
removed SNPs with MAF < 1% and information content ≤0.3, leaving approximately 8.2 
million SNPs.  
 
Statistical Analyses 
Phenotype distribution was visualized using PASW 18 (SPSS Inc).  Association 
analyses for ISENS were performed within AD cases using ProbABEL (Aulchenko, 
Struchalin et al. 2010)  in R 2.14.1 (R Core Team 2012).  ProbABEL is unique in its 
ability to deal with related individuals, imputed genotypes and quantitative traits. To 
account for relatedness in the IASPSAD sample, ProbABEL calculates a kinship matrix.  
It then uses a two-step mixed model to perform linear regression.  Sex and age at 
interview were included as covariates and residuals were used in the regression 
analysis.  P-values were calculated using the Wald test.  Based on the estimated 1.6 
million independent tests in the 1000 Genomes dataset, genome-wide significance was 
set at 3.06x10-8 (Li, Yeung et al. 2012).  The false discovery rate (FDR) was calculated 
using the QVALUE package (Storey, Tibshirani 2003)  in R (R Core Team 2012).  
Gene-based analyses were performed using the Versatile Gene-Based test for 
Genome-wide Association Studies (VEGAS) program.  The program assigns SNPs to 
genes, accounts for LD through a series of Monte Carlo simulations and calculates an 
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empirical gene-based test statistic for each gene (Liu, McRae et al. 2010).  The authors 
suggest a Bonferroni-corrected significance threshold of p<2.83x10-6 (17,787 genes 
tested).  
 
Results 
Figure 4.1 shows the distribution of ISENS values in the IASPSAD GWAS sample.  
ISENS scores range from 1 to 27.8 with a mean of 6.2 drinks to feel an effect.  Though 
there is a wide distribution of values, overall the values are quite high, representative of 
the severely affected nature of the ascertained AD cases in the IASPSAD sample.  
Figures 4.2 and 4.3 show the QQ plot and Manhattan plot, respectively, for 
ISENS association analyses.  Nineteen SNPs were genome-wide significant (Table 4.1) 
and FDR q-values suggest a negligible false positive rate among them.  The top SNP, 
rs143419076 (p=2.7x10-12), is intronic to GPLD1 on chromosome 6.  Of the remaining 
eighteen SNPs, thirteen are intergenic.  Rs184237132, rs75163186, rs189396701, 
rs11553355 and rs138694682 are intronic to ABCA9, AADACL4, STOX, CERKL/ITGA4 
and KIAA0368, respectively.  Gene-based analysis yielded no genes passing Bonferroni 
correction (p<2.8x10-6).  Thirteen genes had q-values ≤ 0.11 and all were located in the 
same region of chromosome 5 in one of two clusters (Table 4.2).  
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Figure 4.1. Distribution of ISENS values in the IASPSAD (n=680). 
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Figure 4.2. QQ plot for ISENS.  The red line represents distribution under the null 
hypothesis of no association. λ= 0.999. 
 
 
 
 
Figure 4.3. Manhattan plot for ISENS. The red line represents genome-wide 
significance at p≤3.06x10-8.  
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Table 4.1. SNPs associated with ISENS surviving multiple testing correction. 
 
 
 
 
 
 
 
 74 
 
Table 4.2. Results for ISENS gene-based association.  
 
All genes have q-value < 0.11. 
 
 
 
Discussion 
This chapter presents results from a GWAS of ISENS in the IASPSAD sample.  There 
were a wide distribution of ISENS values in the sample, but most were quite high with a 
mean of 6.2 and a maximum of 28 drinks needed to feel an effect.  The GWAS 
identified nineteen genome-wide significant SNPs. The top SNP, rs143419076 
(p=2.7x10
-12
), is intronic to GPLD1. GPLD1, Glycosylphosphatidylinositol specific 
phospholipase D1, is an enzyme which degrades glycosylphosphatidylinositol (GPI) 
Chr Gene Start Stop No. SNPs p-Value TopSNP SNP p-Value
5 HARS 140033673 140051155 90 4.80E-05 rs2531359 1.92E-06
5 HARS2 140051201 140059074 75 2.30E-05 rs2531348 1.75E-06
5 ZMAT2 140060215 140066423 70 2.10E-05 rs2531348 1.75E-06
5 PCDHA1 140146059 140372113 227 3.20E-05 rs2531348 1.75E-06
5 PCDHA2 140154627 140372113 215 5.40E-05 rs991918 1.79E-05
5 PCDHA3 140160966 140372113 214 5.50E-05 rs991918 1.79E-05
5 PCDHA4 140166855 140372113 210 6.20E-05 rs991918 1.79E-05
5 PCDHA5 140181544 140372113 206 5.00E-05 rs991918 1.79E-05
5 PCDHA6 140187833 140372113 202 6.50E-05 rs991918 1.79E-05
5 PCDHA7 140194152 140372113 197 6.00E-05 rs991918 1.79E-05
5 PCDHA8 140201090 140372113 185 6.50E-05 rs991918 1.79E-05
5 PCDHA9 140207540 140372113 179 7.60E-05 rs991918 1.79E-05
5 PCDHA10 140215817 140372113 166 9.40E-05 rs991918 1.79E-05
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anchors, detaching proteins from the plasma membrane.  It is predominately expressed 
in the liver (Schofield, Rademacher 2000).  The actions of GPLD1 are involved in 
second messenger signaling, protein level homeostasis and protein activity (Nosjean, 
Briolay et al. 1997).  Rs18834155, 5’ to the gene, and rs9467160, intronic to GPLD1, 
are associated with liver enzymes and liver disease ((Chambers, Zhang et al. 2011) and 
(Yuan, Waterworth et al. 2008), respectively).  No reports linking the gene to initial 
sensitivity were found in the literature.  However, an oligonucleotide array study in the 
Stanley Foundation Brain Bank sample found GPLD1 messenger RNA (mRNA) 
expression was increased in the middle temporal gyrus of alcoholics compared to 
controls (Sokolov, Jiang et al. 2003).                               
Five additional genome-wide significant SNPs in the GWAS implicate six 
additional loci in ISENS in our sample. AADACL4 and STOX1 have no known link, 
direct or indirect, to ISENS or AD.  AADACL4, arylacetamide deacetylase-like, is 
uncharacterized in humans.  STOX1, storkhead box 1, is a winged helix domain 
containing transcription factor and is a risk locus for pre-eclampsia (van Dijk, van Bezu 
et al. 2010).  KIAA0368 and ABCA9 have some evidence of involvement in alcohol-
related phenotypes.  KIAA0368, proteasome-associated protein ECM29 homolog, 
associates with the 26S proteasome and is hypothesized to direct it to cellular locations 
needing rapid protein degradation (Gorbea, Goellner et al. 2004).  In mice, Kiaa0368 is 
correlated with brain levels of the neurosteroid Deoxycorticosterone (DOC). 
Interestingly, DOC levels in mice increase after acute ethanol administration and 
decrease with ethanol dependence (Porcu, O'Buckley et al. 2011).  ABCA9, ATP-
binding cassette sub-family A member 9, encodes a protein which transports molecules 
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across cellular membranes and is expressed in the brain (Piehler, Kaminski et al. 2002). 
The exact function of ABCA9 is yet to be determined, but it is hypothesized to be 
involved in lipid transport (Piehler, Ozcurumez et al. 2012) .  In a recent report, Bettinger 
et al implicated changes in the lipid environment of Caenorhabditis elegans in the acute 
tolerance to ethanol (Bettinger, Leung et al. 2012).                              . 
The remaining genes implicated in the GWAS were CERKL and ITGA4.  The 
genome-wide significant SNP rs11553355 is located in the 3-UTR of both genes.  The 
function of CERKL, ceramide kinase-like, is still uncharacterized, however CERKL 
mutations are associated with cone-rod dystrophy (CRD) and recessive, nonsyndromic 
retinitis pigmentosa (RP26) (Mandal, Tran et al. 2012).  ITGA4, integrin alpha 4, is a 
member of the integrin family.  Integrins function as membrane spanning adhesion 
receptors.  The protein encoded by ITGA4, the α4 chain, dimerizes with one of two beta 
chains.  The α4β1 integrin is integral for hematopoiesis (Arroyo, Yang et al. 1999)                                  
and is associated with central nervous system (CNS) inflammation, migration of 
lymphocytes (Correia, Coutinho et al. 2009), autism (Correia, Coutinho et al. 2009) and 
poor prognosis in leukemia (Shanafelt, Geyer et al. 2008).  Interestingly, ITGA4 is 
located in a significant quantitative trait locus (QTL) for acute ethanol sensitivity in BXD 
recombinant inbred mouse lines (Guo, Webb et al. 2009, Palmer, Lessov-Schlaggar et 
al. 2006), a phenotype directly comparable to the ISENS phenotype analyzed in our 
human sample. 
In addition to the GWAS SNP results, gene-based association analyses yielded 
two clusters of genes on chromosome 5 associated with ISENS.  One cluster is 
comprised of ZMAT2, HARS2, HARS and DND1, none of which have known relevance 
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to ISENS, AD or addiction.  The second cluster is comprised of ten protocadherin 
isoform precursors, PCDH1-10.  Protocadherins are integral membrane and adhesion 
proteins that function within the brain as cell connectors (Sano, Tanihara et al. 1993).  In 
mice, multiple PCDH isoforms were reportedly associated with cocaine exposure and 
withdrawal:  PCDH1, PCDH5 and PCDH10 expression increased during cocaine 
exposure and withdrawal while PCDH2 and PCDH6-9 expression increased during 
cocaine withdrawal, only (Eipper-Mains, Kiraly et al. 2012).  There are no reports in the 
literature for involvement of these protocadherins in initial sensitivity to alcohol.  
However, PCDH9 is located within a QTL for chronic alcohol withdrawal in mice (Guo, 
Webb et al. 2009, Bergeson, Kyle Warren et al. 2003). 
The thirteen remaining genome-wide significant SNPs are intergenic.  Three of 
these SNPs (rs144574114, rs145567095 and rs149656664) are located within the ARP 
linkage region in the IASPSAD sample on chromosome 1.  In fact, two of the three 
SNPs (rs144574114 and rs149656664) are located specifically within the initial 
sensitivity linkage peak itself (chr1: 101,685,305-111,184,618).  Further research is 
necessary to examine whether the SNPs lie within DNA regulatory regions, microRNAs 
or are in LD with any known loci. 
In summary, a GWAS of ISENS yielded multiple genome-wide significant SNPs. 
Six SNPs were located in known loci.  AADACL4, STOX1, GPLD1, KIAA0368, ABCA9 
and CERKL represent new potential risk loci for ISENS.  The final gene, ITGA4, has 
been implicated in acute sensitivity to ethanol in mice but this is the first known report of 
an association in humans.  Gene-based analysis also implicated several loci in ISENS 
including a family of protocadherins that had been previously linked with addiction and 
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alcohol withdrawal.  The IASPSAD is a severely affected, ascertained sample and 
therefore these results need to be explored in a population sample to determine 
applicability.  The associated SNPs from the GWAS had low MAF, ranging from 1-4%.  
Therefore, these results may need to be interpreted with caution.  The IASPSAD 
sample size limits power to detect these smaller effect sizes and it is possible that a 
small number of genotypes could be artificially inflating the association results.  
However, in several instances the genome-wide significant SNPs were clustered in the 
same chromosomal region, indicating a true signal and arguing against artificial 
inflation.  Replication in other human datasets would strengthen the association results 
and molecular characterization is necessary to untangle the role of each associated loci 
in the ISENS phenotype in our sample.   
 
Future Directions 
These results represent the initial GWAS analysis of the ISENS phenotype in the 
IASPSAD sample.  There are multiple additional studies to be undertaken.  A thorough 
analysis of SNPs in LD with the top SNPs is integral to analysis of the data.  Top SNPs 
in LD with other associated SNPs are more indicative of a true association.  Genes 
associated with ISENS in our sample will be checked for association with AD as well.  
As mentioned previously, replication will be attempted in COGA and other samples to 
strengthen the association results.  Candidate genes from previous studies of ISENS 
will be examined in the data, possibly by weighting these results and re-analyzing the 
data.  For significantly associated loci, messenger RNA (mRNA) differences will be 
assessed in postmortem brain samples from chronic alcoholics and controls.  Also, 
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Association LIst Go AnnoTatOR (ALIGATOR) will be run in the dataset to identify 
pathways and Gene Ontology (GO) groups that are overrepresented (Holmans, Green 
et al. 2009).   
Finally, a major strength of physiological phenotypes in human research is their 
application to model organisms.  The results from this analysis have not been explored 
in depth in the model organism literature to see what existing data reveals.  It may also 
be worthwhile to examine genes of interest in model organisms represented within the 
VCU Alcohol Research Center.  Particularly in Drosophila melanogaster and 
Caenorhabditis elegans, expression of loci can be knocked down (or knocked out) and 
changes in acute tolerance and initial sensitivity reliably measured. 
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CHAPTER FIVE 
 
A Genome-wide Association Study of Maximum Alcohol Consumption in the Irish 
Affected Sib Pair Study of Alcohol Dependence 
 
 
Introduction 
Maximum alcohol consumption in a twenty-four period (MAX24) is a physiological 
phenotype related to Alcohol Dependence (AD) and is positively correlated with risk for 
alcohol use disorders (Dawson, Grant et al. 2005) .  Schuckit et al have found that the 
maximum number of drinks in a day was fifty percent higher among AD cases with 
withdrawal and tolerance (characterized as a more severe class) than AD cases 
endorsing  neither (Schuckit, Tipp et al. 1995) .  Findings from several studies have 
shown that MAX24 is heritable.  In a twin study of US Vietnam veterans, heritability was 
estimated at around thirty-five percent (Slutske, True et al. 1999).  Saccone et al 
reported that in an unpublished adult twin study by Heath et al the heritability was 
estimated to be fifty percent (Saccone, Kwon et al. 2000).  Furthermore,  in the 
Collaborative Study of the Genetics of Alcoholism (COGA), the correlation between 
siblings was indicative of a genetic component to the MAX24 phenotype (~0.4 in same-
sex sibling pairs) (Saccone, Kwon et al. 2000).   
Previous genetic analyses of maximum alcohol consumption have implicated 
numerous chromosomal regions and candidate loci.  Linkage analyses in the COGA 
sample found linkage to a region on chromosome 4 including the ADH gene cluster 
(Saccone, Kwon et al. 2000), a region on chromosome 7 encompassing TAS2R38 and 
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CHRM2 (Saccone, Saccone et al. 2005)  and to chromosomes 10 and 13 (de Andrade, 
Olswold et al. 2005).  In the Framingham Heart Study, linkage was found with markers 
on chromosomes 1,4,6,7,9,12,15,16,17 and 22.  The top hit was on chromosome 9 near 
TRPM3 (Bergen, Yang et al. 2003).  Linkage analysis in the Irish Affected Sib Pair 
Study of Alcohol Dependence (IASPSAD) implicated chromosomes 12 and 18 (Kuo, 
Neale et al. 2006).  Two candidate gene studies have examined association with 
alcohol metabolism genes and the MAX24 phenotype.  In the Collaborative Genetic 
Study of Nicotine Dependence (COGEND), association was found with single 
nucleotide polymorphisms (SNPs)  in ADH1B, ADH7, ALDH5A, ALDH1A2, and 
ALDH1A3 (Sherva, Rice et al. 2009).  MacGregor et al found association with 
rs1229984 within ADH1B (Macgregor, Lind et al. 2009).  A non-synonomous coding 
SNP within a bitter taste receptor gene, hTAS2R16, is also reported to be associated 
with AD and maximum alcohol consumption (Hinrichs, Wang et al. 2006).  Finally, two 
genome-wide association studies (GWAS) of MAX24 found significant association with 
rs2140418, intronic to ANKS1A (Heath, Whitfield et al. 2011) and two SNPs within 
ASKRD7 (Chen, Xiong et al. 2012). 
MAX24 is an alcohol-related phenotype shown to be associated with the severity 
and prevalence of alcohol use disorders. In light of these facts, and because of the 
documented heritability of the trait, we examined MAX24 in our sample.  This chapter 
presents data from a GWAS on MAX24 in the IASPSAD sample.  Single SNP 
association analysis and gene-based association analysis are used to identify loci 
associated with risk for the phenotype.   
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Methods 
Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) 
A detailed description of the sample is provided elsewhere (Prescott, Sullivan et 
al. 2006).  Briefly, probands were ascertained in clinical treatment facilities and hospitals 
in the Republic of Ireland and Northern Ireland between 1998 and 2002.  Probands 
were interviewed using an adapted version of the Semi-Structured Assessment of the 
Genetics of Alcoholism (SSAGA) and diagnosed with Alcohol Dependence (AD) using 
DSM-IV criteria.   The sample is ethnically homogenous; a stipulation for inclusion in the 
study required each proband have all 4 grandparents born in Ireland, Northern Ireland, 
Scotland, Wales or England.  
 
Maximum Drinking Phenotype 
Maximum alcohol consumption (MAX24), the largest number of drinks an 
individual reported consuming in 24 hours, was extracted from the SSAGA. Because 
units in Ireland differ from those in the United States, participants were asked to 
describe the type of beverage and volume consumed and this was converted into 
standard drinks (i.e., 12 oz of beer, 4 oz of wine, or 1.5 oz of spirits). 
 
GWAS: Pre-genotyping QC of IASPSAD cases 
DNA from all probands and affected siblings from the IASPSAD was quantified 
using both spectrophotometry and Quant-iT Picogreen (Life Technologies, Carlsbad, 
CA) technology.   200ng of each DNA sample was run on a 2% agarose gel to assess 
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degradation.  Finally, all samples were sex-typed with sex chromosome-specific  
quantitative PCR (qPCR) using the Quantifiler Duo DNA Quantification Kit (Life 
Technologies, Carlsbad, CA).  Only high molecular weight samples (bands > 800bp) 
with DNA concentrations ≥ 50ng/ul and with genotypic sex matching phenotypic sex 
were sent for genotyping.  
 
Genotyping, QC and Calling Algorithms 
815 samples from the IASPSAD, including eleven sets of parents to assess 
Mendelian errors, were sent to Vanderbilt University for genotyping on Affymetrix v6.0 
arrays (Santa Clara, CA).  2000 Biobank controls from the Irish Blood Transfusion 
Service were also genotyped on Affymetrix v6.0 arrays at either the Affymetrix or Broad 
Institute core facilities.   Arrays were called used the Affymetrix Birdseed v2 algorithm.  
Thirty-five samples were removed post-genotyping for CQC values <0.4, Nsp/Sty CQC 
values < 0 or discrepant genotypic sex calls.  Arrays were then re-called using 
BEAGLECALL software (Browning, Yu 2009)  in an effort to minimize site differences in 
genotyping.  BEAGLECALL is an iterative process which starts with the fluorescent 
intensity calls and then incorporates haplotypic information from the sample with 
increasingly stringent calling filters. Subsequently, samples and SNPs underwent a 
thorough QC process.  Samples were removed if the phenotypic and genotypic sex 
were discordant, they had excessive Mendelian errors, they were ancestry, 
heterozygosity or mean pi-hat outliers, their call rates were ≤ 98%, or if there was a 
DNA mix-up.  SNPs were removed if HWE p-values < 1x10-6, the minor allele frequency 
(MAF) < 1%, there were Mendelian errors, they were duplicates, their call rate < 98% or 
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if there was differential missingness between cases and controls. After QC, 676,736 
SNPs were available for 710 probands and affected siblings and 1755 controls. 
 
Imputation 
Genotypes were imputed using IMPUTE2 (Howie, Donnelly et al. 2009)                                               
with the March 2012 1000 Genomes reference haplotype panel (1000 Genomes Project 
Consortium 2010).   Probabilities were converted to dosages (based on number of 
minor alleles) using MACH2 (Scott, Mohlke et al. 2007).  Post-imputation filtering 
removed SNPs with MAF < 1% and information content ≤ 3%, leaving approximately 8.2 
million SNPs.  
 
Statistical Analyses 
Phenotype distribution was visualized using PASW 18 (SPSS Inc). Association 
analyses for MAX24 were performed within AD cases using ProbABEL (Aulchenko, 
Struchalin et al. 2010)  in R 2.14.1 (R Core Team 2012).  ProbABEL is unique in its 
ability to deal with related individuals, imputed genotypes and quantitative traits. To 
account for relatedness in the IASPSAD sample, ProbABEL calculates a kinship matrix.  
It then uses a two-step mixed model to perform linear regression. Sex and age at 
interview were included as covariates and residuals were used in the regression 
analysis.  P-values were calculated using the Wald test. Based on the estimated 1.6 
million independent tests in the 1000 Genomes dataset, genome-wide significance was 
set at 3.06x10-8 (Li, Yeung et al. 2012) .  The false discovery rate (FDR) was calculated 
using the QVALUE package (Storey, Tibshirani 2003) in R (R Core Team 2012).  Gene-
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based analyses were performed using the Versatile Gene-Based test for Genome-wide 
Association Studies (VEGAS) program.  The program assigns SNPs to genes, accounts 
for LD through a series of Monte Carlo simulations, and calculates an empirical gene-
based test statistic for each gene (Liu, McRae et al. 2010).  The authors suggest a 
Bonferroni-corrected significance threshold of  p<2.83x10-6 (17,787 genes tested).  
 
Results 
Figure 5.1 shows the distribution of MAX24 values in the IASPSAD GWAS sample. 
MAX24 values range from 9 to 171 with a mean of 39.33 drinks in a twenty-four hour 
period.  Though there is a wide distribution, overall the values are quite high, 
representative of the severely affected nature of the ascertained AD cases in the 
IASPSAD sample.  
Figures 5.2 and 5.3 show the QQ plot and Manhattan plot, respectively, for 
MAX24 association analyses.  There were twelve genome-wide significant SNPs, 
shown in Table 5.1.   The top SNP, rs151338448 (p=9.52x10-12), is intronic to CCZ1B 
on chromosome 7.  Rs117223671, rs188264442 and rs75214636 are intronic to 
SNTG1, PIK3R3 and ACOXL, respectively.   Eight SNPs were intergenic and all 
clustered within approximately 100kb of SNTG1.  Gene-based analysis yielded one 
gene, CREBBP on chromosome 16, that passed multiple testing correction (Table 5.2).  
Four other genes had FDR q-values less than 0.11 and all are located in a cluster on 
chromosome 1. 
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Figure 5.1. Distribution of MAX24 values in the IASPSAD (n=709). 
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Figure 5.2. QQ plot for MAX24.  The red line represents distribution under the null 
hypothesis of no association. λ= 0.999. 
 
 
Figure 5.3.  Manhattan plot for MAX24. The red line represents genome-wide 
significance at p≤3.06x10-8.  
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Table 5.1. SNPs associated with MAX24 surviving multiple testing correction. 
 
 
 
 
Table 5.2. Results for MAX24 gene-based association. 
 
 
 
 
 
Chr. SNP Position (bp) MAF Gene p-Value q-Value
7 rs151338448 6862684 0.013 CCZ1B 9.52E-12 7.77E-05
8 rs191199258 50686000 0.015 6.29E-09 0.0110
8 rs117958407 50766599 0.016 6.44E-09 0.0110
8 rs74805105 50655986 0.016 6.62E-09 0.0110
8 rs76062094 50727424 0.015 6.81E-09 0.0110
8 rs117223671 50844885 0.014 SNTG1 1.28E-08 0.0167
1 rs188264442 46561551 0.010 PIK3R3 1.43E-08 0.0167
8 rs76936715 50806542 0.015 1.91E-08 0.0175
8 rs117015298 50806924 0.015 1.93E-08 0.0175
8 rs117455144 50780280 0.015 2.39E-08 0.0195
2 rs75214636 111602132 0.019 ACOXL 2.64E-08 0.0196
15 rs79326577 53190651 0.027 2.95E-08 0.0201
Chr. Gene Start Stop No.SNPs p-Value q-Value TopSNP SNP p-Value
16 CREBBP 3715056 3870122 124 <10
-6
0 rs129966 0.00038
1 MYCBP 39101222 39111637 104 2.10E-05 0.1055 rs4246511 1.64E-05
1 RRAGC 39077605 39097927 98 2.40E-05 0.1055 rs9439079 3.26E-05
1 RHBDL2 39124065 39180043 124 3.60E-05 0.1055 rs4246511 1.64E-05
1 GJA9 39112325 39119876 104 3.80E-05 0.1055 rs4246511 1.64E-05
 89 
 
Discussion 
We performed a GWAS of MAX24 in our IASPSAD sample.  There was a wide 
distribution of MAX24 values in the sample, but most were quite high with a mean of 39 
and a maximum of 171 drinks in a twenty-four period.  These values are comparable to 
the distribution seen in the COGA sample.  Saccone et al reported an average of 29.5 
drinks in a twenty-four hour period with a maximum value of 336 (Saccone, Kwon et al. 
2000).  In a non-ascertained sample, COGEND, the average maximum number of 
drinks in a twenty-four hour period was 16 overall, but 23 in males (Sherva, Rice et al. 
2009).  
The top SNP from the association analysis, rs151338448 (p=9.52x10-12), is 
intronic to CCZ1B.  CCZ1B, CCZ1 vacuolar protein trafficking and biogenesis 
associated homolog B (S. cerevisiae), and CCZI, CCZ1 vacuolar protein trafficking and 
biogenesis associated homolog (S. cerevisiae), encode identical proteins, are located 
873kb apart on chromosome 7, and are uncharacterized in humans but highly 
conserved in animals and plants.  The yeast homolog of CCZ1 is integral to multiple 
vacuole processes (Wang, Stromhaug et al. 2002).  In the mouse and Caenorhabditis 
elegans, the homolog for CCZ1 has been implicated in the processing and digestion of 
apoptotic cells (Kinchen, Ravichandran 2010, Nieto, Almendinger et al. 2010).  There 
are no known reports linking CCZ1B or CCZ1 to alcohol consumption or AD.  
Three other genes were implicated in the MAX24 SNP association analysis. 
SNTG1, γ1-syntrophin gene, belongs to the syntrophin family and the encoded protein 
is expressed only in neuronal cells (Piluso, Mirabella et al. 2000, Bashiardes, Veile et al. 
2004).  Disruption of SNTG1 has been documented in both scoliosis (Bashiardes, Veile 
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et al. 2004) and lung cancer in non-smokers (Job, Bernheim et al. 2010), but there are 
no references regarding this locus and MAX24 or AD.  Although representing an indirect 
link, SNTG1 binds the neurotrophic protein ENO2, localizes it to the plasma membrane, 
and is crucial for its functioning (Hafner, Obermajer et al. 2010).  ENO2 protein 
expression is decreased in heroin addicts compared to controls (Liao, Cheng et al. 
2011).  Similar pathways can be perturbed in addicts across drugs of abuse and 
perhaps this alternation is present in AD individuals as well. 
PIK3R3, phosphoinositide-3-kinase regulatory subunit 3 (gamma), is in the lipid 
kinase family.  These kinases have a plethora of functions within the cell (Koutros, 
Schumacher et al. 2010).  Multiple sources report overexpression of PIK3R3 in gastric 
(Zhou, Chen et al. 2012), brain (Soroceanu, Kharbanda et al. 2007) and ovarian 
(Zhang, Huang et al. 2007) cancers and PIK3R3 is associated with plaque formation in 
the brains of Alzheimer’s patients (Liang, Dunckley et al. 2008).  PIK3R3 is necessary 
for IGF2 function (Soroceanu, Kharbanda et al. 2007).  Igf2 protein expression is 
decreased in mouse embryos following alcohol exposure (Downing, Johnson et al. 
2011) and IGF2 expression is statistically different in human children with prenatal 
alcohol exposure compared to unexposed children (Aros, Mills et al. 2011).  Finally, the 
rat ortholog of PIK3R3 was reported to have lower expression in the nucleus 
accumbens of alcohol-preferring rats self-administering ethanol compared to the same 
strain of rat self-administering saccharine (Rodd, Kimpel et al. 2008, Guo, Webb et al. 
2009). This suggests that PIK3R3 may be an ethanol responsive gene. 
The final gene implicated in the MAX24 SNP association analysis is ACOXL. 
ACOXL, acyl-CoA oxidase-like, is uncharacterized in humans and has no known or 
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postulated role in maximum volume of alcohol consumed or AD. SNP variation in the 
gene is associated with risk of chronic lymphocytic leukemia in English (Di Bernardo, 
Crowther-Swanepoel et al. 2008), Chinese (Lan, Au et al. 2010), Spanish and Swedish 
(Crowther-Swanepoel, Mansouri et al. 2010) patients.   
In addition to the genome-wide significant SNP results, gene-based analysis 
implicated five other genes in MAX24 in our sample (Table 2).  CREBBP, CREB binding 
protein, on chromosome 16 was significantly associated after multiple testing correction.  
CREBPP binds CREB (cAMP response element binding protein) and facilitates its 
activation of  cyclic adenosine monophosphate (cAMP) -responsive genes (Barnby, 
Abbott et al. 2005).  Phosphorylation of CREBBP is integral in the well-documented 
ethanol-induced increase in cAMP signaling (Constantinescu, Wu et al. 2004) and has 
been implicated in a chromatin remodeling model of alcoholism (Pandey, Ugale et al. 
2008).  A human association study in heroin and alcohol addicts from India suggested 
that a SNP within CREBBP may be a risk factor for addiction (Kumar, Deb et al. 2011).   
In relation to alcohol consumption, Crebbp was identified in a quantitative trait loci (QTL) 
study of high and low alcohol-drinking rats (Bice, Liang et al. 2010).   
Four other genes had FDR q-values less than 0.11 in the gene-based 
association analysis of MAX24: MYCBP, RRAGC, RHBDL2 and GJA9.  RRAGC, Ras-
related GTP binding C, has previous implications with alcoholic myopathy caused by 
heavy drinking.  Briefly, ethanol increases RRAGC association with a key protein 
synthesis regulator, mechanistic target of rapamycin (MTOR).   In so doing, ethanol 
causes a change in MTOR and decreases overall protein synthesis (Hong-Brown, 
Brown et al. 2012).  RHBDL2, rhomboid, veinlet-like 2 (Drosophila), was reported to be 
 92 
 
differentially expressed in the frontal cortex of alcoholics compared to non-alcoholics 
(Guo, Webb et al. 2009, Liu, Lewohl et al. 2006).  The remaining genes have no known 
relationship with any alcohol-related phenotypes. 
 A GWAS of MAX24 yielded multiple genome-wide significant SNPs.  Four SNPs 
were located in known loci.  CCZIB, SNTG1, PIK3R3 and ACOXL represent new 
candidate loci for maximum alcohol consumed in twenty-four hours and possibly AD.  
Gene-based association analyses identified a loci, CREBBP, associated with MAX24 
that has a rich history in the addiction literature.  Although no SNPs within CREBBP 
reached genome-wide significance in the SNP association analysis, the aggregate 
association of multiple variants within the gene resulted in a significant gene-based test 
statistic.  This suggests the power and utility of gene-based analyses.  The IASPSAD is 
a severely affected, ascertained sample and therefore these results need to be explored 
in a population sample to determine applicability.  The twelve genome-wide significant 
SNPs from the GWAS had low MAF, ranging from 1-3%.  These results may need to be 
interpreted with caution.  The IASPSAD sample size limits power to detect these smaller 
effect sizes and it is possible that a small number of genotypes could be artificially 
inflating the association results.  However, the number of SNPs clustering on 
chromosome 8 in the genome-wide significant results argues against that, at least in 
one case.  Replication in other human datasets would strengthen the association results 
and molecular characterization is necessary to untangle the role of each associated loci 
in the MAX24 phenotype in our sample.   
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Future Directions 
These results represent the initial GWAS analysis of the MAX24 phenotype in the 
IASPSAD sample.  There are multiple additional studies to be undertaken. As noted 
earlier, values for the MAX24 phenotype are quite high and may represent an over-
inflation in reported values.  One method to account for this inflation is transformation of 
the data, prior to association analyses, as suggested in Saccone et al (Saccone, Kwon 
et al. 2000).  A thorough analysis of SNPs in linkage disequilibrium (LD) with the top 
SNPs is integral to analysis of the data.  Top SNPs in LD with other associated SNPs 
are more indicative of a true association.  Genes associated with MAX24 in our sample 
will be followed-up for association with AD as well.  As mentioned previously, replication 
will be attempted in the COGA sample to strengthen the association results.  Candidate 
genes from previous studies of MAX24 and the linkage regions implicated in the 
IASPSAD sample will be examined in the data, possibly by weighting these results and 
re-analyzing the data.  For significantly associated loci, messenger RNA (mRNA) 
differences will be assessed in postmortem brain samples from chronic alcoholics and 
controls.  Also, Association LIst Go AnnoTatOR (ALIGATOR) will be run in the dataset 
to identify pathways and Gene Ontology groups that are overrepresented (Holmans, 
Green et al. 2009).   
Finally, a major strength of physiological phenotypes in human research is their 
easier application to model organisms.  The results presented here-in have not yet been 
explored in-depth in the model organism literature.  It may also be worthwhile to 
examine genes of interest in model organisms represented within the VCU Alcohol 
Research Center.  
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CHAPTER SIX 
 
Examination of the Shared Variation Between Alcohol Dependence, Major 
Depression and Neuroticism  
 
Introduction 
Previous chapters have examined genetic risk factors for alcohol dependence (AD) and 
multiple alcohol-related phenotypes (ARPs) including alcohol craving and initial 
sensitivity.   Examining these physiological traits which correlate with risk is integral to 
understanding the phenotypic complexity of AD.  However, it is also prudent to consider 
the high levels of comorbidity seen with AD.  A wide range of common psychiatric and 
substance use disorders are seen in AD individuals.  In concert with ARPs, it is only by 
understanding the relationship between AD and comorbid phenotypes, and the genetic 
architecture contributing to each, that researchers can begin to untangle the genetics of 
alcohol use disorders.  This chapter presents ongoing work in examining the 
relationship between AD and comorbid internalizing disorders.   
Comorbidity is the norm rather than the exception in common psychiatric (e.g. 
major depression) and substance use disorders (e.g. alcohol dependence)(Kessler, 
Nelson et al. 1996, Regier, Farmer et al. 1990).  Internalizing disorders, characterized 
by negative mood states, include major depression, dysthymia, generalized anxiety 
disorder and phobias. Externalizing disorders, characterized by acting out and 
behavioral disinhibition, include substance use disorders, adult antisocial personality 
disorder and conduct disorder.  AD correlates most strongly with the externalizing 
disorders, but is significantly correlated with internalizing disorders as well (Kessler, 
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Nelson et al. 1996, Kessler, Crum et al. 1997, Kessler, Chiu et al. 2005, Regier, Farmer 
et al. 1990, Dawson, Goldstein et al. 2010).  Furthermore, a recent examination in the 
National Epidemiological Survey on Alcohol and Related Conditions (NESARC) showed 
that one-third of alcohol-related problems and outcomes were explained by the shared 
variation seen amongst internalizing disorders (Kushner, Wall et al. 2012).  Given the 
high levels of comorbidity seen in these disorders, it is not unreasonable to hypothesize 
they share genetic liability.  A seminal paper by Kendler et al examined externalizing 
and internalizing disorders in a Virginia twin sample.  Within their data, one common 
genetic factor loaded onto the externalizing disorders, including AD, and, though the 
architecture was more complex, one common genetic factor loaded onto the 
internalizing disorders (Kendler, Heath et al. 1992).  Although AD was related most 
strongly to the externalizing factor, there was a significant, though smaller, loading of 
the common internalizing genetic factor onto AD.  A final piece of evidence supporting 
the relationship between AD and both externalizing and internalizing disorders is found 
in the phenotypic differences among alcoholics.  
 Numerous studies have examined typologies of AD individuals.  Perhaps the 
most well-known classification system is that of Cloninger who identified two types of 
alcoholics:  Type I alcoholics had a milder form of alcoholism, a later onset of the 
disease and were more sensitive to the environment whereas Type II alcoholics had a 
more severe form of alcoholism, were typically male, and were more likely to have had 
criminal problems (Cloninger, Bohman et al. 1981, Saunders 1982).  Using Cloninger’s 
typology, later studies reported that Type II alcoholics were also more likely to exhibit 
externalizing behaviors like substance abuse and antisocial personality disorder 
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(Hallman, von Knorring et al. 1996, von Knorring, Bohman et al. 1985).  Other well-
known classification systems have found similar phenotypic stratifications.  Zucker’s 
model divided alcoholics into four groups, two of which were antisocial alcoholism and 
negative affect alcoholism (Zucker 1986).  Windle et al also defined four types of 
alcoholism: mild, polydrug, negative affect and antisocial (Windle, Scheidt 2004).  Both 
Lesch and Del Boca’s typologies included subgroups with depression and anxiety and 
others with behavioral disturbances and antisocial personality.  Though there have been 
numerous classifications of alcoholics, and much debate as to the best system, a 
general theme is that there exist at least two types of alcoholics.  One group, which 
could be called the “internalizers”, drink to alleviate negative mood states whereas 
another group, the “externalizers”, drink as part of their overall behavioral disinhibition.   
Although the literature suggests that AD is more strongly correlated with externalizing 
disorders, due to the high levels of comorbidity seen between AD and internalizing 
disorders, the known differences in types of alcoholics and the documented shared 
genetic factors, it is of interest to examine genetic risk loci that are associated with risk 
for this broader phenotypic liability. 
 This chapter focuses on understanding the shared variation between AD, major 
depression (MD) and neuroticism.   AD has been discussed extensively in the 
Introduction.  MD is defined by the fourth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) as a depressed mood or loss of interest for at 
least two weeks and at least four of the following nine symptoms during that same 
period: depressed mood, anhedonia, weight changes, sleep changes, motor 
disturbances, fatique, feelings of worthlessness or guilt, difficulty concentrating and 
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recurrent thoughts of death and suicide (American Psychiatric Association 2000).  
Neuroticism is a personality trait characterized by emotional distress. Feelings of 
nervousness, guilt and depression are felt by persons with high levels of neuroticism as 
are emotional instability and low self-esteem (Wray, Middeldorp et al. 2008).  
 The comorbidity seen between AD and MD is well established.  Petrakis et al 
reported individuals with AD in the Epidemiologic Catchment Area (ECA) study and 
National Comorbidity Survey (NCS) were 3.9 times more likely in the past year to have 
had MD in comparison to those without AD (Petrakis, Gonzalez et al. 2002, Regier, 
Farmer et al. 1990, Kessler, Nelson et al. 1996).  Similarly, the National Longitudinal 
Alcohol Epidemiological Survey (NLAES) found that individuals with AD were 4.2 times 
more likely in the previous year to have reported MD (Hasin, Grant 2002).  In the 
NESARC, individuals with AD were 3.7 times more like to have MD in the previous year 
(Grant, Dawson et al. 2004).  Although there have been numerous studies looking for 
genetic risk factors of AD and MD independently, fewer studies have looked at the 
comorbid phenotype.  Nurnberger et al found linkage to chromosome 1 for individuals 
with either AD or MD, suggesting that there were genetic risk factors in this region that 
could affect risk for both phenotypes (Nurnberger, Foroud et al. 2002).  Candidate gene 
studies have found association between CHRM2 (Wang, Hinrichs et al. 2004) and 
SLC6A4 (Marques, Hutz et al. 2006)  in both AD and MD.   Interestingly, a study in a 
Han Chinese sample found that the DRD2 gene was associated with subjects endorsing 
AD, MD and anxiety but not in subjects with only AD, MD or anxiety (Huang, Lin et al. 
2004).  Kertes et al examined an array of candidate genes in comorbid individuals and 
found evidence of association with CRHBP, OPRM1 and GABRB1 (Kertes, Kalsi et al. 
 98 
 
2011).  The only genome-wide association study (GWAS) of AD and MD was recently 
published by Edwards et al.  No single nucleotide polymorphisms (SNPs) were genome-
wide significant, but pathway analyses revealed enrichment of glutamatergic function 
genes (Edwards, Aliev et al. 2012).   
Neuroticism is strongly correlated with the internalizing disorder spectrum 
(Bienvenu, Brown et al. 2001) and high levels of neuroticism have been reported to 
predict higher numbers of internalizing symptoms (Andrews, Stewart et al. 1990).  A 
Virginia twin study by Hettema et al found that a common genetic factor for the 
internalizing disorders also significantly loaded onto neuroticism (Hettema, Neale et al. 
2006).  The literature also reports that neuroticism is correlated with future MD episodes 
(Hirschfeld, Klerman et al. 1989, Boyce, Parker et al. 1991) and AD.  An English twin 
study found higher neuroticism  scores in drinking versus non-drinking twins (Mullan, 
Gurling et al. 1986)  and a separate group found high levels of neuroticism were 
correlated with an increased risk for AD (Loukas, Krull et al. 2000).  Numerous studies 
have used linkage, candidate gene association studies and GWAS to investigate 
genetic risk factors for AD and neuroticism separately, but at least two studies have 
assessed genetic risk factors for both phenotypes within the same sample.  Rs7590720, 
in the PECR gene, is associated with both AD and neuroticism in a German sample 
(Grabe, Mahler et al. 2011) and substance dependent African American females 
showed association between ADH1A and neuroticism (Zuo, Gelernter et al. 2010).   
 Within this chapter, preliminary results from the IASPSAD and COGA samples 
are presented which examine the relationship between AD, MD and neuroticism.  Factor 
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analysis is used to identify shared variation and preliminary invariance modeling is 
explored to compare latent mean differences between groups.   
 
Methods 
Samples: Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) 
A detailed description of the sample is provided elsewhere (Prescott, Sullivan et 
al. 2006).  Briefly, probands were ascertained in clinical treatment facilities and hospitals 
in the Republic of Ireland and Northern Ireland between 1998 and 2002.  Probands 
were interviewed using an adapted version of the Semi-Structured Assessment of the 
Genetics of Alcoholism (SSAGA) and diagnosed with AD using DSM-IV criteria.   The 
sample is ethnically homogenous; a stipulation for inclusion in the study required each 
proband have all 4 grandparents born in Ireland, Northern Ireland, Scotland, Wales or 
England.  From the original linkage sample, 710 probands and affected siblings are 
used in this study.   
 
Samples: Collaborative Study on the Genetics of Alcoholism (COGA) 
Probands for the COGA sample, details of which are described elsewhere (Dick, 
Plunkett et al. 2006), were recruited throughout the United States in 6 geographic 
locations from alcohol treatment programs.  Large families were preferentially 
ascertained with a proband required to have 2 or more family members in the COGA 
sampling area and preferably sibships greater than 3.  All individuals were given the 
SSAGA interview and AD diagnosed using DSM-IV criteria. From the larger COGA 
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sample, 847 genetically independent AD cases and 552 controls of European ancestry 
were used.   
 
Phenotypes 
AD and MD were measured identically in both samples, using the SSAGA 
interview.  Symptom counts for each were used for factor analysis. Two different, but 
related, measures of neuroticism were used in the IASPSAD and COGA samples.  The 
IASPSAD sample used the Eysenck Personality Questionairre-Revised-Shortened 
(EPQ-RS) (Eysenck, Eysenck et al. 1985).  The EPQ-RS is a yes/no self-report form 
with twelve questions regarding neuroticism.  The COGA sample used the NEO Five-
Factor Inventory (NEO-FFI) (Costa Jr., McCrae 1992).  The NEO-FFI has twelve items 
regarding neuroticism, each using a five point Likert scale.  In each sample, sum scores 
for neuroticism were used for factor analysis.  N=706 AD cases, 698 individuals with MD 
symptoms and 677 people with neuroticism scores in the IASPSAD sample.  N= 844 AD 
cases, 844 individuals with MD symptoms and 567 people with neuroticism scores in 
the COGA sample. 
 
Factor analysis 
All analyses described within this section were done separately, but identically, in 
each sample unless otherwise noted.  All three variables (AD symptom count, MD 
symptom count and neuroticism sum scores) were non-normal and therefore ordinalized 
in PASW18 (SPSS Inc.) prior to factor analysis.  Factor analysis was performed in 
Mplus (Muthén, Muthén 1998-2011) using the weighted least squares means and 
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variances adjusted (WLSMV) estimator.  The WLSMV is a two stage process and is well 
suited for non-normal and ordinal data (Muthén, du Toit et al. accepted for publication). 
It operates by first estimating a pairwise variable by variable polychoric matrix from 
which it creates an unobserved latent variable, for each observed variable, that is 
assumed to be normally distributed.  From these additional latent response variables, 
the WLSMV fits the model. Males and females were run together and sample 
identification (IASPSAD or COGA) was used as a grouping variable.  As the IASPSAD 
sample included siblings, the cluster option was used.  In the COGA sample, each 
sample was given its own family number. 
 
Invariance modeling factor analysis 
To calibrate factor scores between groups, invariance modeling was performed 
in Mplus in addition to all previously discussed coding options. In the baseline, saturated 
model, all metrics were unrestrained.  In the full invariance model, factor loadings and 
thresholds were held invariant between the IASPSAD and COGA samples.  In the 
partial invariance models, one variable’s factor loadings and thresholds were allowed to 
be variant between samples.  Using the DIFFTEST metric in Mplus, a test statistic was 
created for each nested model, comparing fit to the baseline model.  Model fit was also 
assessed using the Comparitive Fit Index (CFI), Tucker-Lewis Index (TLI), and Root 
Mean Square Error Approximation (RMSEA).  CFI and TLI values between 0.90 and 
0.95 are considered acceptable while values between 0.95 and 1 are considered good.  
RMSEA values ≤0.05 are considered good and ≤0.10 acceptable (Levine, Petrides et al. 
2005, Hu, Bentler 1995) 
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.   
 
Statistical Analyses 
Phenotype distribution visualization and correlations were performed using 
PASW 18 (SPSS Inc).  
 
Results 
In the IASPSAD, the average AD symptom count was 6.43 and the average MD 
symptom count 5.88.  Neuroticism sum scores ranged from 0 to 12 with a mean of 8.11.  
In the COGA sample, 5.62 was the average AD symptom count.  The average MD 
symptom count was 4.97.  Neuroticism sum scores ranged from 26 to 74 with a mean of 
58.  All phenotypes were significantly correlated with each other (Table 6.1).  All 
variable distributions showed a non-normal distribution (Figure 6.1).  To combat this 
non-normality, values were ordinalized: AD into three groups, MD into four and 
neuroticism into five.   
 
 
Table 6.1. Correlations between phenotypes in the IASPSAD and COGA.  
 
All correlations were significant at the 0.01 level (2-tailed).  ADsx= AD symptom count, 
MDsx = MD symptom count and Nss = neuroticism sum scores. 
 
IASPSAD COGA
ADsx MDsx Nss ADsx MDsx Nss
ADsx 1 ADsx 1
MDsx 0.252 1 MDsx 0.204 1
Nss 0.304 0.299 1 Nss 0.184 0.339 1
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Factor analysis was performed in each sample using the ordinalized AD, MD and 
neuroticism phenotypes.  The factor loadings were similar across samples (Table 6.2).  
MD symptom count loaded very strongly onto the factor (0.7 and 0.717 in the IASPSAD 
and COGA samples, respectively).  AD symptom count loaded moderately well onto the 
factor (0.544 and 0.420 in the IASPSAD and COGA samples, respectively) and 
neuroticism loaded fairly well onto the factor (0.554 and 0.495 in the IASPSAD and 
COGA samples, respectively).   
 
 
 
 
Table 6.2. Factor loadings on the common factor.  
                          
 
ADsx= AD symptom counts, MDsx = MD symptom counts, and Nss = neuroticism sum 
scores. 
 
 
 
 
 
 
 
IASPSAD COGA
ADsx 0.544 0.420
MDsx 0.702 0.717
Nss 0.554 0.495
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      IASPSAD               COGA 
 
Alcohol Dependence symptoms (3-7) 
 
Major Depression symptoms (0-9) 
 
Neuroticism sum scores (varies) 
 
 
Figure 6.1. Phenotype distributions in the IASPSAD and COGA. 
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Discussion 
This chapter presents preliminary data from a factor analysis of AD, MD and 
neuroticism in the IASPSAD and COGA samples.  Neuroticism was measured with the 
EPQ-RS in the IASPASD sample and the NEO-FFI in the COGA sample.  Both forms 
probe feelings of anxiety and depression.  However, the NEO-FFI also asks about angry 
hostility, self-consiousness, impulsiveness and vulnerability.  A review of the literature 
indicates that multiple measures of neuroticism can be appropriately combined within a 
study.  A general population cohort from Scotland (n=207) was administered both 
interviews. The phenotypic correlation was 0.89 (Gow, 2005).  In an Australian twin 
study, individuals were given the EPQ-RS in 1989 and NEO-FFI in 2002.  The genetic 
correlation was 0.88 (Wray, 2008).  All data in the literature suggests that there is a 
positive phenotypic and genetic correlation between the two indices of neuroticism used 
in the study.   
The phenotypic distributions of AD, MD and neuroticism were all non-normal.  AD 
and neuroticism were skewed to the right as would be expected in a sample ascertained 
for AD.  The distribution of MD symptoms, in each sample, showed a large number of 
individuals with no symptoms.  Among the rest of the subjects, the distribution of 
symptoms was skewed to the right.  This is likely an artifact of the interview process: if 
an individual failed to meet criteria during two screening questions, no further symptoms 
of MD were queried.  This resulted in a large number of individuals with no MD 
symptoms. The remainder of the MD distribution is due to the severely affected, 
ascertained nature of the samples used in this study. 
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Factor analysis was used to examine the shared variation between AD, MD and 
neuroticism.  Simply put, factor analysis is a data reduction technique that attempts to 
find patterns in the data; groups of data that function like each other (Fabrigar, Wegener 
et al. Psychological Methods).   A common factor was derived, explaining a large 
amount of the variance for MD and a smaller amount of the variance for AD and 
neuroticism.  The nature of the factor loadings make it unclear if the common factor is 
adequately measuring the shared variation between the disorders.  Especially in the 
COGA sample, the factor loadings for AD and neuroticism (0.420 and 0.495, 
respectively) are quite modest.  It is hypothesized that the current analysis is not the 
most effective way to analyze the data.  As will be discussed in the Future Directions 
section, an item level factor analysis will shed light on the underlying structure of the 
variables in each sample and inform which statistical method is best suited for further 
research. 
There are several other aspects of this study that warrant further discussion.  
First, both samples contain comorbid cases whose MD and AD did not occur 
independently of each other.   Therefore these people do not meet the classical criteria 
for MD.  Edwards et al, defines these individuals as having a depressive syndrome 
rather than MD (Edwards, Aliev et al. 2012).  Secondly, the temporal relationship 
between AD and MD in each sample is not addressed.   In the literature, the nature of 
the genetic liability for internalizing disorders and AD is still unclear.  It remains to be 
determined if certain loci predispose individuals to both AD and MD or rather if certain 
genes predispose individuals to one which then leads to the other.  It is also possible 
that both hypotheses are correct and some genetic risk factors do predispose persons 
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to a broader comorbidity and other risk factors are disorder specific.   The literature 
contains studies that have found MD indicative of future AD (Kuo, Gardner et al. 2006, 
Sihvola, Rose et al. 2008)  and others that suggest AD leads to MD (Fergusson, Boden 
et al. 2011, Schuckit, Smith et al. 2007).  In the IASPSAD, Kertes et al reported that the 
relationship was murky (Kertes, Kalsi et al. 2011) and in the COGA sample, Edwards et 
al reported that in a majority of the females, MD preceded AD (Edwards, Aliev et al. 
2012).  It will be of use to examine this in the particular sample subsets used to 
determine the nature of the relationships.  It is unlikely we will have power to split up the 
sample into different groups, but it will be useful to inform our analyses. 
 
 
FUTURE DIRECTIONS 
In order to inform comparisons between the IASPSAD and COGA, and to calibrate 
factor scores between the samples (Milfont, Fischer 2010), preliminary invariance 
modeling was performed.  In the baseline model, all metrics were unrestrained. (This is 
the model presented in the chapter results.)  In the full invariance model, factor loadings 
and thresholds were held invariant between the IASPSAD and COGA samples.  In the 
partial invariance models, one variable’s factor loadings and thresholds were allowed to 
be variant (“free”) between samples while the rest remained invariant.  The model fitting 
results are reported in Table 6.3 where a significant p-value corresponds to a model 
fitting significantly worse than the baseline model.  The full invariance model fit was 
poor.  A partial invariance model with AD symptom count unrestrained, but MD and 
neuroticism invariant, was not significantly different than the baseline model. Therefore, 
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it was chosen as the best fitting model.  The factor loadings under this model are 
presented in Table 6.4 
. 
 
 
Table 6.3. Invariance modeling results.  
 
N = neuroticism. 
 
 
 
 
 
Table 6.4. Factor loadings using the partial invariance model with AD variant.  
                                  
ADsx= AD symptom counts, MDsx = MD symptom counts, and Nss = neuroticism sum 
scores. 
 
 
 
 
CFI TLI RMSEA Chi-square df p-value
Full invariance 0.607 0.633 0.156 139.347 7 0.0000
Partial_ADfree 0.984 0.984 0.035 11.605 6 0.0714
Partial_MDfree 0.672 0.606 0.169 115.968 5 0.0000
Partial_Nfree 0.732 0.597 0.171 94.490 4 0.0000
IASPSAD COGA
ADsx 0.556 0.386
MDsx 0.804 0.804
Nss 0.477 0.477
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Several problems are evident. The best model was a partial invariance model 
with MD and neuroticism invariant and AD loadings and thresholds allowed to vary 
between samples. Traditionally, researchers have tested the full invariance model and if 
the fit was poor, no further tests were done.  The idea of partial invariance modeling 
was developed by Muthen et al in 1981 (Muthen, Christoffersson 1981)  and was 
subsequently shown to allow for comparison of variables between groups (Byrne, 
Shavelson et al. 1989).  Partial invariance modeling has gained acceptance in the field, 
however the number of variable items allowed in the model is still unresolved (Millsap, 
Kwok 2004).  Bryne et al reported that a majority of the items in the factor analysis must 
be invariant (Byrne, Shavelson et al. 1989)  while Reise et al reported that one-half of 
the items should be invariant (Reise, Widaman et al. 1993).  Recent work has 
suggested that model size (the number of items being tested) is also integral to the 
validity and effectiveness of partial invariance modeling (Donahue 2006).  The partial 
invariance model presented in this chapter was comprised of only three items and so 
may be psychometrically invalid.  Furthermore, even when using the partial invariance 
model, the factor loadings are again troublesome.  In the COGA sample, AD symptom 
count loads very weakly (0.386) onto the common factor suggesting that factor is not 
capturing a substantial amount of variance in the trait. 
 Current research is ongoing to address these issues. Instead of using symptom 
counts and sum scores, an item level factor analysis will be done using invariance 
modeling and grouping by sex and sample (IASPSAD vs. COGA).  The item level data 
for neuroticism is unavailable in the COGA sample, so the analysis will focus on AD and 
MD, only.  Item level analysis will allow for examination of patterns in the data and a 
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more direct, concrete knowledge of the phenotype specifically being measured in the 
analysis.  Once the best-fitting model is chosen, GWAS, meta-analysis and gene-based 
association analyses can be re-run in both samples.  Importantly, pathway-based 
analysis will be performed to see if groups of genes associated with common 
functionality are replicated between samples.  
In conclusion, this chapter presents preliminary data from work done in two 
ascertained samples: the IASPSAD and COGA.   Factor analysis was used to examine 
shared variation between AD, MD and neuroticism.  Work continues to improve the 
factor analysis model for internalizing disorders and AD.  Previous work has been done 
in the IASPSAD looking at externalizing disorders and AD (Hack et al, unpublished), 
while previous chapters have examined biochemical risk factors for AD.  When all 
analyses are complete, there will be a more global picture of risk pathways for AD in the 
IASPSAD sample. 
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CHAPTER SEVEN 
 
Global Conclusions and Future Directions 
This dissertation has presented multiple alternative strategies to identifying genetic risk 
factors for Alcohol Dependence (AD) and alcohol-related phenotypes.  Chapter Two 
reports association between variants in GPSM1 and craving-related behaviors, 
suggesting that the model organism literature provides a targeted, improved method for 
selection of candidate genes in addiction research.  Chapter Three details significant 
association between two loci on chromosome 7, KIAA1324L and GRM3, and AD in 
addition to significant gene expression differences in GRM3 between chronic alcoholics 
and controls.  This region on chromosome 7 was identified in a pooled genome-wide 
association study (GWAS), illustrating the utility of GWAS studies to identify new risk 
loci.  The remainder of the dissertation is focused on genome-wide analyses of 
physiological traits and comorbid phenotypes correlated with risk for AD within the Irish 
Affected Sib Pair Study of Alcohol Dependence (IASPSAD).  Chapter Four examines 
initial sensitivity, Chapter Five, maximum alcohol consumption in twenty-four hours and 
Chapter Six, comorbidity between AD, major depression and neuroticism.   
 Three overall themes emerge from this dissertation regarding phenotypic 
complexity and GWAS methodology.  First, in the two GWAS performed in this 
dissertation, there are no overlapping single nucleotide polymorphisms (SNPs) or loci in 
the top results. Furthermore, there are no overlapping signals in the top results between 
any of these analyses and an unpublished GWAS of AD in the IASPSAD sample (Hack 
et al, unpublished results).  This suggests, at least within the IASPSAD, that different 
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genetic risk loci predispose individuals to different alcohol-related phenotypes. Also, the 
diagnostic phenotype of AD does not identify these risk factors.  Therefore, it is 
imperative that alcohol researchers adequately define their phenotypes and take into 
account comorbidity within their samples.  Proper measurement of phenotypes of 
interest may necessitate advanced structural equation modeling, as discussed in 
Chapter Six. 
 Secondly, results from the initial sensitivity (Chapter Four) GWAS suggest loci 
affecting risk for this phenotype are involved in basic, ubiquitous cell signaling.  
Genome-wide significant variants were located within genes whose functions included 
degradation of proteins, transport of molecules and cell-to-cell connections.  If it is true, 
these results suggest a very complex molecular biology of the phenotype involving 
numerous loci.  Many of the loci may have other loci in the genome with compensatory 
roles.  This complexity may help explain the missing heritability described in the 
literature and discussed below. 
 Lastly, the two GWAS analyses presented in this dissertation were successful in 
spite of a relatively small sample size (n=710 AD cases).  Although further examination 
of association signals in linkage disequilibrium (LD) with top SNPs and replication in 
other datasets is still needed, the GWAS of initial sensitivity identified nineteen genome-
wide significant SNPs and maximum consumption, twelve genome-wide significant 
SNPs.  Before and after genotyping, IASPSAD samples were subjected to a thorough 
QC process. Additionally, samples were called using both fluorescence intensity (the 
common method) and LD information.  The rigorous QC and calling process is 
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hypothesized to have reduced noise within the sample, through elimination of poorly 
performing samples and SNPs, and resulted in significant, high quality results. 
GWAS have identified a number of potential genetic risk factors for AD and 
related phenotypes. However, there are two conspicuous limitations: a lack of 
replication and the issue of “missing heritability’:  identified variants explaining a minimal 
amount of variance in the trait.  An often used example is that of height. Unlike alcohol 
dependence, and many other complex disorders, height is an unambiguous phenotype 
that can be reliably and directly measured.  Despite this, as of 2011 it was estimated 
that 180 loci identified in GWAS for height explained only 12% of the variance in the trait 
(Lander 2011).  Currently, collaborations are being planned to perform GWAS on 
alcohol-related phenotypes in large samples of thousands of individuals (Agrawal, 
Freedman et al. 2012).  This increase in power should enable better identification of the 
many genetic risk loci hypothesized to affect risk for these phenotypes (Spencer, Su et 
al. 2009).  However, as this dissertation suggests, it will be imperative that researchers 
thoroughly QC their data beforehand and, if re-calling of genotypes is attempted, that 
site differences be identified and addressed.  
Alternatively, the problem of missing heritability could be the result of a flaw in 
the accepted model of complex inheritance. As discussed in the Introduction, the GWAS 
era is based on the common disease - common variant (CDCV) hypothesis wherein a 
large number of loci of small effect size contribute to risk for AD.  In contrast, the 
common disease – rare variant (CDRV) model hypothesizes that a few rare variants of 
large effect contribute to the risk for AD (Rowe, Tenesa 2012).  It seems plausible, as 
hypothesized by some researchers (e.g. (Gibson 2012)) that both models operate 
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simultaneously.  Rare variation has not been well studied in AD but the advancing 
technology and decreasing cost of exome sequencing should result in a wealth of large 
datasets in the next few years. 
Finally, gene expression studies can be used to either identify differentially 
expressed loci in alcoholics compared to controls or to study a candidate loci’s 
involvement in a phenotype of interest.  Human postmortem brain tissue banks and 
array technology have allowed for large-scale examinations of messenger RNA (mRNA) 
expression (Crabbe 2008).  Brain regions studied for differences between alcoholics 
and controls include the frontal cortex (Liu, Lewohl et al. 2006, Lewohl, Wang et al. 
2000), nucleus accumbens (Flatscher-Bader, van der Brug et al. 2005), hippocampus 
(Enoch, Zhou et al. 2012) and amygdala (Ponomarev, Wang et al. 2012).  These 
studies have typically found large numbers of differentially expressed genes and 
implicated major signaling pathways like GABAergic and glutamatergic 
neurotransmission.  By using convergent lines of evidence such as GWAS data, exome 
sequencing and gene expression, researchers will be able to comprehensively 
investigate genetic risk factors for AD and related phenotypes. 
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